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Reconstitution of CMV-specific immunity following transplant remains a primary clinical 27 
objective to prevent CMV disease, and adoptive immunotherapy of CMV-specific T cells can be 28 
an effective therapeutic approach. Due to viral persistence, most CMV-specific CD8pos T cells 29 
become terminally differentiated effector cells (TEFF). A minor subset retains a memory-like 30 
phenotype (TM), but it is unknown whether these cells retain memory function or persist over 31 
time. Interestingly, recent studies suggest that CMV-specific CD8pos T cells with different 32 
phenotypes have different abilities to reconstitute sustained immunity following transfer. The 33 
immunology of human CMV (HCMV) infections is reflected in the murine model (MCMV). We 34 
found that HCMV- and MCMV-specific T cells displayed shared genetic programs, validating 35 
the MCMV model for studies of CMV-specific T cells in vivo. The MCMV-specific TM 36 
population was stable over time and retained a proliferative capacity that was vastly superior to 37 
TEFF cells. Strikingly, after transfer, TM cells established sustained and diverse T cell populations 38 
even after multiple challenges. Although both TEFF and TM cells could protect Rag-/- mice, only 39 
TM cells persisted after transfer into immune replete, latently-infected recipients and responded if 40 
recipient immunity was lost. Interestingly, transferred TM cells did not expand until recipient 41 
immunity was lost, supporting that competition limits the antigen stimulation of TM cells. 42 
Ultimately, these data show that CMV-specific TM cells retain memory function during MCMV 43 
infection and can reestablish CMV immunity when necessary. Thus, TM cells may be a critical 44 










Latent Cytomegalovirus (CMV) is present within a large percentage of the population but is 52 
effectively controlled by the immune system (1-6). However, in transplant patients, immune 53 
suppression can allow CMV reactivations to progress to disease and increase mortality. Despite 54 
the advancements of anti-viral medications, long-term prevention of CMV disease is dependent 55 
on the reconstitution of CMV-specific immunity, which can be achieved through adoptive 56 
immunotherapy (5-18). 57 
 58 
In adoptive immunotherapy, healthy CMV-seropositive donors provide CMV-specific T cells to 59 
an immune suppressed recipient. Due to the persistent nature of CMV infection, CMV-60 
seropositive donors accumulate large numbers of CMV-specific CD8pos T cells (approximately 61 
5-10% of the total CD8pos T cells), a process termed “memory inflation," (19-28). Studies in 62 
humans and the well-characterized mouse model (MCMV) have shown that the majority of 63 
inflationary populations are composed of terminally differentiated effector phenotype (TEFF) T 64 
cells that presumably develop as a result of repeated antigen stimulation and may not possess the 65 
proliferative or survival capacity necessary for long-term maintenance of CMV immunity (22, 66 
27, 29-34). Interestingly however, a fraction of these inflationary T cells retain a memory-like 67 
(TM) phenotype, despite sharing epitope specificity and T cell receptor sequences with the TEFF 68 
subset (23, 25, 35-37). Studies with other infection models have shown that such a memory 69 
phenotype can identify cells that have “stem-cell like” characteristics (38, 39). If this model 70 
holds true for CMV immunity, the CMV-specific TM cells would be ideal to use in an adoptive 71 
immunotherapy setting. Recent evidence supports this hypothesis. In a non-human primate 72 
model, CMV-specific effector T cells that were expanded in vitro from sorted TM cell had a 73 
superior ability to survive after adoptive transfer (40). Moreover, a human study showed a 74 




long-term maintenance of donor derived cells (41).  76 
 77 
The goal of our study was to utilize the mouse model (MCMV) to directly address the capacity 78 
of the CMV-specific TM population to restore long-term CMV-specific immunity after transfer. 79 
Importantly, we found that the MCMV-specific TM cells share a common genetic program with 80 
their human CMV-specific counterparts and that these cells could repeatedly restore long-term 81 
CMV-specific immunity under a spectrum of transfer scenarios. Our data suggest that adoptive 82 
immunotherapy with CMV-specific TM cells will improve consistency and clinical outcomes in 83 




















Materials and Methods 101 
Mice 102 
Unless otherwise indicated, C57BL/6 mice, CD45.1 mice (B6.SJL-Ptprca Pepcb/BoyJ), Thy1.1 103 
mice (B6.PL-Thy1a/CyJ) and Rag-/- mice (B6.129S7-Rag1<tm1Mom>J) were purchased from 104 
Jackson Laboratory. OT-I transgenic mice (C57BL/6-Tg(TcraTcrb)1100Mjb/J) also purchased 105 
from Jackson, were bred with CD45.1 mice to produce double positive (CD45.2pos/CD45.1pos) 106 
OT-I mice. All protocols were approved by the Thomas Jefferson University Institutional 107 
Animal Care and Use Committee. 108 
 109 
Infections 110 
Unless otherwise indicated, mice were infected intraperitoneally (i.p.) with 2 x 105 pfu of 111 
MCMV strain MW97.01 (42). Mice were considered latently-infected at 8 weeks post-infection. 112 
Rag-/- mice were infected with 5 x 104 pfu of MCMV-TK virus (43). OT-I T cell transfer 113 
recipients were challenged with 2 x 105 pfu MCMV-SL8, which expresses the SIINFEKL 114 
peptide (44, 45). 115 
 116 
Tetramer Staining, Antibodies and FACS Analysis 117 
MHC-tetramers were provided by the NIH Tetramer Core Facility 118 
(http://tetramer.yerkes.emory.edu/) and have been described previously (27). Staining was 119 
performed as described previously (27) with tetramers and the following antibodies: [CD8(53-120 
6.7); CD44(IM7); CD27(LG.3A10); CD127(A7R34); KLRG1(2F1); CD62L(MEL-14); 121 
CD45.1(A20); CD45.1(104); Thy1.1(OX-7); Thy1.2(30-H12); IFN-γ(XMG1.2); TNF−α(MP6-122 
XT22); CD107a(1D4B)]. In all cases, samples were collected on an LSR II and analyzed with 123 
FlowJo software (Tree Star). The gating strategy for phenotypic characterization of tetramerpos 124 




frequency of singlets. Tetramerpos cells were identified as a frequency of CD8pos cells. A B8R 126 
tetramer (specific for the B8R peptide from Vaccinia), was used as a negative tetramer control. 127 
Tetramerpos cells were phenotypically defined by they expression of KLRG1, CD27, CD127 or 128 
CD62L. 129 
 130 
Adoptive Transfers 131 
CD8pos splenocytes from latently-infected donors were enriched using EasySep Biotin selection 132 
kit (StemCell Technologies) and biotinylated antibodies against RBCs(Ter119), CD4(GK1.5) and 133 
CD19(6D5) according to the recommended protocol. Enriched cells were stained to determine 134 
the frequency of tetramerpos cells within the enriched fraction and then sorted on either a MoFlo 135 
(Dako Cytomation) or an ARIA II (BD Biosciences) cell sorter. Sorted cells were counted, and 5 136 
x 104 cells were transferred via the retro-orbital sinus. Sort purity was analyzed on an LSR II. 137 
The number of transferred tetramer-binding CD8pos T cells was estimated using the tetramer 138 
frequency within the enriched CD8pos population and the post-sort purity analysis. Fold change 139 
was calculated as the number of tetramer-binding T cells in the spleen 7 days post-challenge over 140 
the total number of tetramerpos cells transferred (assuming 100% engraftment). The gating 141 
strategy for analyzing donor cells in the recipients was identical to that described above with 142 
antibodies specific for the relevant congenic marker (CD45.1 or Thy1.2).  143 
 144 
For OT-I adoptive transfers, splenocytes from naive mice containing 600 OT-I T cells were 145 
transferred. Recipients were challenged with MCMV-SL8. To establish secondary and tertiary 146 
populations, OT-I TM CD8pos T cells were FACS sorted and transferred as described in 147 
Supplemental Figure 1 and the legend for Figure 5. Following challenge with MCMV-SL8, the 148 
frequencies of donor OT-Is were determined in the blood of recipients using the strategy 149 




expression CD45.1 and Vα2. 151 
 152 
Intracellular Stimulation (ICS) 153 
ICS and staining was performed as previously described (27, 45), with minor modifications. 154 
Specifically, cells were incubated with 1 µg/mL peptide (Genemed Synthesis), 1 µg/mL 155 
brefeldin A (GolgiPlug, BD Biosciences) and CD107a-specific antibody for 3 hours. 156 
 157 
CD70 Blocking Antibody Treatment 158 
CD70 antibody blockade was performed as previously described (46), with minor modifications. 159 
Briefly, mice received either 150 µg of anti-CD70(FR70) or control rat IgG2b (both from 160 
BioXCell) via the i.p. route. Injections were administered at days -1, 0 and 3 post-infection. 161 
 162 
Antibody Depletions 163 
Antibody depletions were performed with Thy1.1(19E12), CD4(GK1.5) and NK1.1(PK136) 164 
antibodies. 300 µg of each antibody were administered i.p. in PBS. Three subsequent injections 165 
of 100 µg of each antibody were given at 7 day intervals. 166 
 167 
Microarray 168 
Splenocytes from latently-infected mice were co-stained with tetramers loaded with the antigenic 169 
peptides from M38, m139 and IE3 (25) and sorted on a MoFlo (Dako Cytomation) cell sorter. 170 
MCMV-specific T cells were identified as CD8pos, CD44hi and tetramer binding and then further 171 
segregated into TM and TEFF cells subsets by expression of KLRG1 and CD127. Naïve CD8pos 172 
cells were CD44lo. Total RNA was isolated using the Qiagen RNAeasy Plus Kit (Qiagen), 173 
quantified on a NanoDrop 2000c Spectrophotometer (Thermo Scientific) and processed at the 174 




biotinylated cDNA was hybridized to Mouse gene 1.0 ST array (Affymetrix). Chips were 176 
scanned on an Affymetrix Gene Chip Scanner 3000 and data were analyzed using the R 177 
programming language and various packages from Bioconductor (47).  The oligo package (48) 178 
was used to extract expression data from the Affymterix CEL files and perform background and 179 
RMA normalization (49).  Annotation information was added using the 180 
mogene10sttranscriptcluster.db (50) package. Probes without valid annotations (7,196 of 35,556 181 
probes) were removed before differential expression analysis using the limma package’s (51) 182 
linear modeling and Bayes methods (52). Genes showing up- or down-regulation of at least two-183 
fold and p-value < 0.05 in each of three contrasts (TEFF vs. Naïve, TM vs. Naïve, and TEFF vs. TM) 184 
were considered for gene set enrichment analysis (GSEA). Microarray data have been deposited 185 
in the Gene Expression Omnibus (GEO) database (53) (accession number: GSE61927) 186 
 187 
Gene Set Enrichment Analysis 188 
Human data for series GSE24151 (54) was retrieved from NCBI’s GEO database (53), extracted 189 
using Partek® Genomics Suite® software, version 6.6 (Partek Inc., St. Louis, MO) and curated 190 
for input into GSEA software (55) (http://www.broadinstitute.org/gsea/). Since the data for 191 
GSE24151 have been deposited in GEO as log10 ratios of the reference pool to sample, each 192 
value was inverted by multiplying by -1. Gene names in the six mouse gene lists (up- or down-193 
regulated in each of the three contrasts described above) were converted to human names using 194 
data from NCBI’s Homologene database, Release 68 195 
(http://www.ncbi.nlm.nih.gov/homologene). The converted gene lists along with genes specific 196 
to the liver and the TCR receptor pathway from the Molecular Signature Database (MSigDB) 197 
(55) were analyzed for enrichment in the human data using recommended settings for the GSEA 198 






MCMV-specific inflationary TM populations are stable and share a common 202 
transcriptional program with HCMV-specific CD8pos T cells in humans 203 
In the mouse model, MCMV infection of C57BL/6 (B6) mice results in inflation of select 204 
MCMV-specific CD8pos T cells specific for peptides from the viral proteins M38, m139 and IE3 205 
(Fig. 1A and (25, 27, 28)). As in humans infected with human CMV (HCMV), the majority of 206 
MCMV-specific inflationary T cells express a TEFF phenotype (often defined as TEMRA in 207 
humans), while only a small fraction express a TM-like phenotype, defined here as 208 
KLRG1lo/CD27hi and further sub-divided into central memory (TCM – CD127hi/CD62Lhi) and 209 
effector memory (TEM – CD127hi/CD62Llo) subsets (Fig. 1A and (22, 23, 27, 29-33, 56)). In 210 
contrast, “non-inflationary” MCMV-specific CD8pos T cell responses, represented by the 211 
response against the viral protein M45, contract after acute infection and are thought to be 212 
maintained by homeostatic mechanisms thereafter (Fig. 1A and (25, 27, 57)). As expected, non-213 
inflators express a predominately memory (TM) phenotype, which also includes both TCM and 214 
TEM subsets (Fig. 1A and (23, 27)). 215 
 216 
It remains unknown whether the constant immune stimulation needed to maintain memory 217 
inflation causes a decline of the TM subset within inflationary populations over time. Using 218 
infection-matched cohorts, we found that the numbers of TM cells that were specific for 219 
inflationary antigens were stable over time and remarkably similar to the numbers of non-220 
inflationary TM cells, despite great differences between the numbers of inflationary and non-221 
inflationary TEFF cells (Fig. 1B, 1C). Thus, although continuous antigen stimulation maintains 222 
memory inflation, the inflationary TM population remains stable. 223 
 224 




in HCMV-infected people. To determine whether MCMV-specific TM and TEFF cells share a 226 
common transcriptional program with their human counterparts, we sorted MCMV-specific TM 227 
(CD44hi/CD127hi/KLRG1lo) and TEFF (CD44hi/CD127lo/KLRG1hi) cells specific for the M38, 228 
m139 and IE3 antigens. Microarray analyses were performed on these cells. Genes that were 229 
significantly up- or down-regulated in TM and TEFF subsets relative to each other or to naïve 230 
(CD44low) T cells, were mapped to the corresponding human genes and compared with the 231 
profiles of HCMV-specific T cells, previously defined by the van Lier group as 232 
CD27hi/CD45RAlo (TM) or CD27lo/CD45RAhi (TEFF) (54). The CD27 and CD127 (IL-7Rα) 233 
molecules both mark CMV-specific T cells with a memory phenotype in mice and humans (27, 234 
29, 32, 58, 59) and nearly all MCMV-specific KLRG1lo/CD27hi cells (TM) co-expressed CD127 235 
(either TCM or TEM, Figure 1A). Gene set enrichment analyses (GSEA) were used to measure the 236 
overall correlation between the mouse and human gene expression data. As shown in Fig. 2A, 237 
genes that distinguished mouse TEFF and TM cells from each other were highly enriched within 238 
the corresponding human data set. That is: genes up-regulated specifically in mouse TM cells 239 
relative to mouse TEFF cells were highly enriched within the genes that distinguish human TM 240 
cells from human TEFF and vice versa. Moreover, relative to naive T cells, mouse genes that were 241 
up and down-regulated by TEFF or TM cells were highly enriched within genes that distinguished 242 
their human counterparts from human naive T cells (Fig. 2B). The analyzed mouse genes and the 243 
core enrichment profiles of each comparison are listed in Supplemental Table 1. Importantly, 244 
several of these genes corresponded to our sorting parameters and the known phenotypes of TM 245 
and TEFF populations. As controls, identical analyses were performed with genes associated with 246 
the T cell receptor signaling pathway or liver and the data exhibited expected patterns (Fig. 2B). 247 
 248 
Overall, these data show that MCMV-specific and HCMV-specific T cells share a common 249 




specific T cells. To our knowledge, this is the first direct comparison of MCMV-specific and 251 
HCMV-specific T cell gene expression profiles.  252 
 253 
The inflationary TM population retains proliferative capacity 254 
To test the proliferative capacity of the TM and TEFF cells, both populations were sorted from 255 
spleens of latently-infected B6 mice (>3 months post-infection) using their differential 256 
expression of KLRG1 and CD27. Sorted cells were transferred into naive congenic recipients 257 
and re-challenged. The M45- and M38-specific TM cells proliferated robustly within 7 days after 258 
challenge, each expanding almost 1000-fold in the spleen alone, assuming 100% engraftment of 259 
the donor cells (Fig. 3A, 3B). In contrast, the M38-specific TEFF population expanded less than 260 
10-fold in the same time period. Importantly, while the TEFF donor cells remained exclusively 261 
KLRG1hi, the TM donor cells produced large numbers of both TEFF and TM progeny (Fig. 3C). In 262 
fact, donor M45- and M38-specific TM phenotype cells were present in the spleen 7 days after 263 
challenge at numbers that were approximately 50 to 100-fold higher than had been transferred 264 
(dotted line, Fig. 3D), indicating expansion of this subset without terminal differentiation. These 265 
data show that MCMV-specific TM cells retain robust proliferative capacity and can produce 266 
phenotypically diverse progeny including new TM-phenotype cells. 267 
 268 
Recent work has shown that interaction between CD27 and its ligand CD70 plays a functional 269 
role in the proliferation of MCMV-specific inflationary T cells (46). To test the contribution of 270 
this interaction specifically within the TM population, we sorted and transferred TM cells as above 271 
and blocked the CD27-CD70 interaction as described in the Methods. Blocking the CD27-CD70 272 
interaction significantly decreased the expansion of the M38- and M45-specific TM cells 7 days 273 
post-challenge by approximately 4- to 6-fold (Fig. 3E), which is in line with the impact of CD70 274 




data further suggest that the majority of proliferative potential of inflationary T cells is contained 276 
within the minor TM subset. It should be noted that even in the presence of CD70 blockade, the 277 
TM population retained a proliferative capacity that was greater than the TEFF population, 278 
suggesting that additional pathways contribute to the total proliferative potential of these cells 279 
(Fig. 3B, 3E and unpublished observations). 280 
 281 
The inflationary TM population persists and can repeatedly recapitulate memory inflation 282 
To determine the ability of the TM donor cells to persist long-term, we tracked the progeny from 283 
TM donor cells in the blood after re-challenge. M38-specific T cells from TM-sorted donors 284 
persisted at high frequencies in recipients, while the M45-specific donor cells contracted after 285 
their initial expansion in the same mice (Fig. 4A, 4B). Despite their initial TM phenotype, the 286 
donor M38-specific T cells largely expressed a TEFF phenotype after challenge (Fig. 4C, 4D), 287 
consistent with a typical “inflationary” population. The population as a whole retained its ability 288 
produce IFN-γ, TNF-α and expose CD107a (Fig. 4E, 4F). Importantly, a small portion of donor 289 
T cells retained their TM phenotype even after this secondary challenge (Fig. 4C, 4D). 290 
 291 
To understand whether these persistent TM phenotype donors continued to be functional, we 292 
turned to the OT-I transgenic system to facilitate sorting and avoid the possible selection of 293 
different T cell clones (Fig. 5A). As shown previously, transferred naive OT-Is undergo inflation 294 
and produce both TM and TEFF progeny after primary challenge with SIINFEKL-expressing 295 
MCMV-SL8 (45). We sorted the TM phenotype OT-I cells that formed after primary challenge, 296 
transferred these cells and challenged the recipients to establish secondary populations 297 
(Supplemental Fig. 1A). As with non-transgenic T cells (Fig. 4), secondary challenge of TM OT-298 
Is induced inflation and TEFF formation as well as a persistent KLRG1lo population 299 




transferred into a 3rd set of naïve recipients and re-challenged. Incredibly, the donor secondary 301 
TM population inflated and produced both KLRG1hi and KLRG1lo progeny following this tertiary 302 
challenge (Fig. 5B-5E).  303 
 304 
Repeated acute viral challenges of small numbers of T cells in naive mice drives TEFF 305 
differentiation (60-63) and indeed the overall frequency of tertiary inflationary cells that retained 306 
a TM phenotype was reduced (Fig. 5E and Supplemental Fig. 1B). However, these tertiary 307 
stimulated OT-Is remained functional, producing both IFN-γ and TNF-α, as well as exposing 308 
CD107a  (Fig. 5F, 5G). These data show that TM phenotype T cells specific for inflationary 309 
antigens can repeatedly recapitulate memory inflation upon viral challenge and produce 310 
functional TEFF and TM progeny. 311 
 312 
Memory and Effector Subsets protect Rag-/- mice 313 
To test the ability of transferred TM cells to protect against a lethal MCMV challenge, TM and 314 
TEFF populations were sorted from latently-infected B6 mice as above and transferred into Rag-/- 315 
recipients. One day later, the Rag-/- recipients were challenged with MCMV-TK, which lacks 316 
the m157 gene and is therefore resistant to NK-mediated control (43). Both transferred TM or 317 
TEFF cells expanded following the challenge and were sufficient to protect the recipients (Fig. 318 
6A, 6B). In contrast, Rag-/- mice that received no T cell therapy became moribund in 2-4 weeks 319 
and had to be sacrificed (Fig. 6B). Notably, the TEFF population, which proliferated very poorly 320 
in immune replete mice (Fig. 3), expanded and persisted in immune deficient hosts for at least 11 321 
weeks post-challenge (Fig. 6A, 6B). However, the TEFF responses lacked M45-specific, non-322 
inflationary T cells (Fig. 6A). These data show that MCMV-specific TM cells are capable of 323 





The TM population can persist long-term and respond when necessary 326 
Patients undergoing hematopoietic stem cell transplantation (HSCT) are most susceptible to late-327 
onset (>100 days) reactivating CMV, as opposed to an acute CMV infection ((12, 64-66) and 328 
reviewed in (67)). Furthermore, transferred CMV-specific T cells will need to compete with host 329 
immunity. Therefore, we developed a model to test whether TM and TEFF subsets could respond 330 
to viral reactivation after a long delay. To this end, TM and TEFF cells were sorted from latently-331 
infected mice (> 3 months post-infection) and transferred into immune replete, infection matched 332 
or naive, congenic recipients differing at the Thy1 locus (Fig. 7A). Following the transfer, the 333 
latently-infected recipients were rested as described in the figure legend. Donor T cells did not 334 
expand dramatically in any animal following transfer (Supplemental Fig. 2A) supporting our 335 
previous conclusion that competition between T cells dictates MCMV-specific T cell expansion 336 
(45). Recipient T cells and NK cells were then eliminated in all mice using a cocktail of 337 
depletion antibodies that targeted the host cells (Thy1.1pos), but left the donor cells (Thy1.2pos) 338 
intact (Fig. 7B and Supplemental Fig. 2B). This depletion protocol did not induce detectible viral 339 
transcription in any animal as assessed by nested RT-PCR (unpublished observations), likely due 340 
to the presence of anti-viral antibodies (68). Despite the 9-12 week rest period, MCMV-specific 341 
donor TM cells responded robustly in all infected recipients after host depletion (Fig. 7C and 7D). 342 
Importantly, donor TM cells did not expand to detectible levels in depleted naive recipients 343 
(Supplemental Fig. 2C). However, viral challenge of naïve mice that received TM donor cells 12 344 
weeks previously induced a robust donor response in 3 of the 4 animals, indicating that the TM 345 
cells persisted in these mice, even without any antigen (Supplemental Fig. 2C). Thus, antigen 346 
rather than homeostatic mechanisms accounts for the donor TM response in infected recipients.  347 
 348 
In marked contrast, after depletion, donor T cells were only detectible in 2 animals that had 349 




(Supplemental Fig. 3A-3C) supported previous work (69) suggesting that the KLRG1-specific 351 
antibody did not induce depletion of the transferred TEFF subset. Thus, the failure of TEFF cells to 352 
expand in this setting is not a sorting artifact, but rather the inability to persist and/or expand in 353 
response to low amounts of viral antigen. 354 
 355 
After expansion, all infected mice that received TM cells had a donor population specific for 356 
multiple epitopes and the progeny had differentiated to form new TEFF populations (Fig. 7E and 357 
unpublished observations). Furthermore, the four tetramers used only stained ~60% of the total 358 
donor population in each animal (Fig. 7E), suggesting that the remaining 40% of each donor 359 
population contained cells specific for additional MCMV antigens. In contrast, in the two 360 
animals in which TEFF donors expanded to detectible levels, each was skewed substantially 361 
towards a single inflationary epitope (Fig. 7E). Since these sorted TEFF populations included 362 
large numbers of T cells specific for M38, m139 and IE3, this “hit-or-miss” expansion of donor 363 
T cells with select specificities implies that a very small number of non-TEFF cells may have 364 
contaminated the transfer. 365 
 366 
In the mice that received TM donor cells, their diverse progeny persisted in recipients for more 367 
than 11 weeks after termination of the depletion regimen, even though host immunity had 368 
returned (Fig. 7F). These data suggest that TM cells with inflationary specificities are capable of 369 
surviving in an environment with very little or no antigen stimulation and then responding as 370 
needed during a period in which the host is immune compromised and viral antigen becomes 371 
available.  372 
 373 
In total, these data show that protective MCMV-specific TM cells persist throughout infection, 374 




the numerically dominant TEFF cells. Since MCMV-specific TM cells share a transcriptional 376 
program with HCMV-specific TM cells, our data suggest that TM cells may be ideal candidates to 377 



























Adoptive immunotherapy using CMV-specific CD8pos T cells can be a successful therapeutic 402 
strategy for combating CMV reactivations (5-18). However, the majority of CMV-specific 403 
CD8pos T cells isolated from healthy donors will express an effector-differentiated phenotype 404 
(CD27lo/CD127lo/CD45RAhi/KLRG-1hi/CD57hi - reviewed in (70)), and in vitro expansion of 405 
CMV-specific T cells drives their differentiation towards an effector phenotype (40). We used 406 
the MCMV model to show that the ability to restore MCMV-immunity is contained almost 407 
entirely within the minor TM subset that retains CD27. Although both TM and TEFF cells protected 408 
Rag-/- mice (Fig. 6), humans are unlikely to remain completely immune depleted like Rag-/- 409 
mice, and bolus CMV infections are of lesser concern than reactivation following 410 
transplantation. The inability of the TEFF population to consistently expand after immune 411 
depletion in latently-infected hosts, suggests that these cells will only be protective under limited 412 
conditions. These data support a previous study in humans that correlated the transfer of CD27hi 413 
CMV-specific T cells with an increased likelihood of T cell persistence and expansion (41). 414 
 415 
To validate the use of the MCMV model, we compared human and mouse MCMV-specific T 416 
cells and show for the first time, to our knowledge, that TM and TEFF populations in mice and 417 
humans share a common transcriptional profile. The power of the GSEA analysis used for this 418 
comparison is that it identifies significant correlations across the entire transcriptional profile, 419 
rather than comparing individual genes. Nevertheless, we expect that future studies examining 420 
conserved and divergent genetic pathways will reveal significant and relevant information about 421 
CMV-specific immunity in mouse and man. These results highlight the usefulness of the MCMV 422 
model to: 1) perform CMV-specific CD8pos T cell functional studies that are difficult or 423 
impossible to perform in humans and 2) provide translational insights into novel or improved 424 





Understanding how CMV-specific T cell immunity is maintained is critical for the improvement 427 
of CMV adoptive immunotherapy. Persistent antigen stimulation from CMV reactivations results 428 
in the majority of inflationary CD8pos T cells developing a TEFF phenotype and function. 429 
However, our previous work showed that unsorted inflationary CD8pos T cells, containing 430 
primarily TEFF cells, declined after transfer into congenic, latently-infected recipients (27). These 431 
data suggest that MCMV-specific TEFF cells are unable to sustain themselves in an immune 432 
replete environment, even in the presence of antigen. Thus, we proposed that the accumulation of 433 
TEFF cells is the result of continual antigen stimulation of the TM population. Our data show that a 434 
small, stable MCMV-specific TM population has strong functional similarities to classical 435 
memory T cells that develop after acute infections. For example, the ability to proliferate in 436 
response to antigen without terminal differentiation is hallmark of functional memory T cells 437 
(71). In addition to producing differentiated progeny that accumulated after MCMV challenge 438 
(Figure 4D), donor TM cells also produced TM phenotype progeny that outnumbered the cells 439 
transferred (Fig. 3C and D) and persisted throughout our observation period (Fig. 4C and D). 440 
These data suggest that MCMV-specific TM cells have the ability to replace themselves even 441 
while producing differentiated progeny in response to antigen. Importantly, this was true through 442 
at least three rounds of stimulation using sorted splenic TM cells (Figure 5). Thus, MCMV-443 
specific TM cells have the capacity to respond repeatedly to viral antigen during this persistent 444 
infection and can recapitulate memory inflation.  445 
 446 
It is interesting that transferred TM cells failed to expand in immune-replete, latently-infected 447 
hosts. Detectible numbers of donor T cells were only evident in one out of six mice prior to 448 
immune depletion (Supplemental Fig. 2A). In this case, the donors were not positive for any of 449 




However, loss of the host T cell populations led to rapid and robust expansion of donor T cells 451 
with diverse specificities and phenotypes in all TM cell recipients (Figure 7). The failure of 452 
transferred TM cells to expand in the presence of host MCMV-specific immunity may reflect the 453 
relative lack of available antigen during the latent phase of MCMV infection. Indeed, viral 454 
reactivations occur in only a fraction of latently-infected cells at any given time, and only rarely 455 
produce infectious viral particles (72, 73). Moreover, we have found that competition between T 456 
cells for access to this limited antigen regulates the expansion of individual T cell clones (45). 457 
Thus, the combination of low antigen and large numbers of MCMV-specific T cells in the 458 
recipients may have "shielded" the majority of the donor TM cells from the ongoing infection – 459 
an idea we have proposed previously (45, 74). Importantly, MCMV antigen is not required for 460 
MCMV-specific TM cell survival. We have previously shown that MCMV-specific TM cells 461 
divide at a consistent rate with or without antigen (28) and our new data (Supplemental Fig. 2C) 462 
show that inflationary TM cells can survive in naïve mice without any antigen. Thus, homeostatic 463 
mechanisms can support the inflationary TM population when it does not have access to antigen, 464 
which may partially explain the preservation of memory function within the TM subset. Taken 465 
together, these data suggest that the highly functional TM population, which can persist without 466 
access to antigen, proliferates robustly and produces new TM cells as well as more differentiated 467 
progeny upon antigen stimulation. 468 
 469 
Overall, our data further support the model that the burden of maintaining memory inflation falls 470 
on the functional TM population, which can provide a stable and consistent source of new TEFF 471 
progeny whenever needed, over for prolonged periods of time. However, T cell competition for 472 
limited antigen appears to prevent the continuous stimulation of most TM cells. Nonetheless, the 473 
TM population is capable of robustly responding if T cell competition is lost - a conclusion with 474 




patients and anti-viral therapy responses make it difficult to predict and standardize CMV 476 
prevention therapies. Our data suggest that the plasticity of the TM population, transferred before 477 
any disease develops, may offer a “personalized” therapy, where the treatment adapts to the 478 
conditions of the patient and responds if and when antigen becomes available. Future studies will 479 
be needed to explore whether the addition of homeostatic cytokines (e.g. IL-15) or 480 
pharmacotherapeutics (e.g. rapamycin (75)) preserves the TM phenotype either in vivo or during 481 
in vitro expansion. 482 
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Figure Legends 797 
Figure 1: The non-inflationary and inflationary CD8pos T cell populations retain similar 798 
numbers of TM phenotype cells. 799 
Cohorts of age-matched B6 female mice were infected with MCMV and sacrificed at the 800 
indicated time points (n = 4 per time point). Tetramer staining and phenotypic analyses were 801 
performed on blood and splenocytes. (A) Frequency of tetramer-binding CD8pos T cells in the 802 
blood at indicated time points. The phenotypic analysis shown was performed at d326 post-803 
infection. TM cells were identified as CD27hi/KLRG1lo. TCM and TEM were further identified as 804 
CD127hi and either CD62Lhi or CD62Llo, respectively. (B) Absolute numbers of KLRG1hi 805 
tetramer-binding CD8pos T cells in the spleen. (C) Absolute numbers of TCM and TEM tetramer-806 
binding CD8pos T cells. Data are displayed as mean ± SEM and represent two independent 807 
experiments. 808 
 809 
Figure 2: Gene Set Enrichment Analyses reveal significant overlap between the 810 
transcriptional profile of CMV-specific T cells in humans and mice. (A) Gene set enrichment 811 
was performed as described in the Methods. Shown are the enrichment plots for mouse genes 812 
that differed in a TEFF vs. TM comparison, plotted relative to human TEFF and TM cells. Values 813 
represent the normalized enrichment score (NES) and Family Wise Error Rate (FWER), which 814 
estimates the probability of a false positive NES. (B) Lists of significantly altered mouse genes 815 
(2-fold up or down and P<.05) were generated for TEFF and TM cells relative to each other and 816 
relative to naive (CD44low) T cells. GSEA analyses were performed with these mouse gene sets 817 
relative to each of the indicated human data sets, rank ordered by expression (see methods). Stars 818 






Figure 3: TM cells dramatically expand 7 days post-challenge and produce both TM and 822 
TEFF progeny.  823 
Age matched B6 mice received either TM or TEFF cells and were challenged with MCMV as 824 
described in the Methods. Spleens were collected 7 days later for analysis. (A) Representative 825 
FACS plots of tetramerpos donors in the spleen 7 days post-challenge. Frequencies in the corner 826 
are relative to total CD8pos cells. (B) Fold change of donor cells in the spleen, calculated as 827 
described in the Methods, 7 days after challenge. As antigen-specific T cells were not sorted, 828 
approximately equal numbers of M38- and M45-specific TM cells were transferred but ~10-fold 829 
more M38-specific TEFF cells were transferred compared with the TM cells. Due to the extremely 830 
low number of M45-specific TEFF transferred and the minimal expansion at day 7, it was not 831 
possible to calculate a comparable fold change value for the M45-specific TEFF population. Data 832 
were collected from two independent experiments (TM: n = 6 total; TEFF: n = 5 total) are shown. 833 
Statistical significance was determined by a Student’s t-test (*** P<.001; **** P<.0001). (C) 834 
Representative FACS plots of M38-specific CD8pos T cell progeny from either TM or TEFF donors 835 
in the spleen at 7 days post-challenge. Frequencies in the corner are relative to M38-specific 836 
CD8pos cells. (D) Absolute number of TM and TEFF phenotypic progeny that were produced from 837 
TM donors. Data are from the same experiments described in (B). (E) Fold change of donor cells 838 
in the spleen following treatment with either isotype control or anti-CD70 antibody. Data were 839 
collected 7 days post-challenge and represent two independent experiments (n = 6 total). 840 
Statistical significance was determined by a Student’s t-test (*** P<.001; **** P<.0001). All 841 
graphical data are displayed as mean ± SEM. 842 
 843 
Figure 4: TM cells reinflate following re-challenge and retain function. 844 
Age matched B6 mice received TM cells and were challenged with MCMV as in the Methods. 845 




(B) Frequencies of tetramer-binding T cells in the blood over time. Data were collected from 847 
three independent experiments (n = 17 total). (C) Representative FACS plot of the phenotype of 848 
donor-derived M38-specific T cells in the blood 126 days post-challenge. (D) Frequencies of 849 
donor-derived, M38-specific TM and TEFF cells in the blood over time. Data are from the same 850 
experiments described in (B). Each line represents an individual mouse. The square datum point 851 
represents a mouse that appeared to lose the donor T cells after day 7 post-challenge, but 852 
effectors appeared ~20 weeks after challenge. (E-F) Intracellular cytokine staining was 853 
performed on splenocytes 221 days post-challenge. Shown are representative FACS plots of 854 
stimulated (with M38 peptide) and unstimulated cells (E) and the frequencies of IFN-γ positive 855 
cells that also express TNF-α and/or CD107a (F).  Data were collected from a single experiment 856 
(n = 5) described above. All graphical data are displayed as mean ± SEM. 857 
 858 
Figure 5: TM cells can reinflate following multiple re-challenges. 859 
(A) Schematic of experimental design. To establish primary OT-I inflationary populations, 600 860 
naïve OT-I T cells expressing CD45.1 were transferred into naïve B6 (CD45.2) recipients 861 
followed by infection with MCMV-SL8 (i.e. primary challenge). Thirteen weeks later, 6,000 TM 862 
phenotype primary OT-Is, isolated by FACS sorting, were transferred into new B6 recipients 863 
followed by MCMV-SL8 challenge (i.e. secondary challenge). This process was repeated a third 864 
time, transferring 3,500 TM OT-Is into naive mice and challenging with MCMV-SL8 (i.e. tertiary 865 
challenge). (B-C) Representative FACS plot of the donor stain 91 days post tertiary challenge 866 
(B) and frequencies of donor OT-Is (relative to total CD8s) in the blood at the indicated time 867 
points after tertiary challenge (C). Data were collected from two independent experiments (n = 868 
12 total). Each line represents an individual mouse. (D-E) Phenotypic analyses of the mice 869 
described in (B-C). Representative FACS plot of the donor stain 30 weeks post-challenge 870 




splenocytes approximately 20 weeks after the tertiary challenge. Shown are representative FACS 872 
plots of stimulated (with SIINFEKL peptide) and unstimulated cells (F) and the frequencies of 873 
IFN-γ positive cells that also express TNF-α and/or CD107a (G). Data were collected from two 874 
independent experiments (n = 12). Data are displayed as mean ± SEM. 875 
 876 
Figure 6: TM and TEFF cells protect Rag-/- mice following an acute MCMV challenge 877 
Age matched Rag-/- mice received either TM or TEFF cells and were challenged with MCMV-TK 878 
as described in the Methods. Mice were monitored daily for signs of morbidity (lethargy, raised 879 
hair and shaking) and sacrificed if they displayed clear signs of morbidity. Data were collected 880 
from two independent experiments. One experiment was carried out until 77 days post-challenge. 881 
A second experiment was censored at 33 days post-challenge.  (A) Representative tetramer 882 
staining of T cells in Rag-/- that received either TM  or TEFF transfers. Data were collected 11 883 
weeks post-challenge. Frequencies are relative to total CD8s. (B) Survival curve (n = 7 for 884 
control group; n = 7 for TM group; n = 6 for TEFF group). Statistical significance was determined 885 
by a log-rank (Mantel-Cox) test (**** P<.0001). 886 
 887 
Figure 7: TM cells persist in latently-infected, immune replete mice and expand when host 888 
immunity is lost. 889 
(A) Schematic of experimental design. Age matched B6 and Thy1.1 mice were infected with 890 
1x106 pfu MCMV-Smith. Following the establishment of viral latency (>8 weeks post-infection), 891 
either TM or TEFF cells from the B6 donors were transferred, as described in the Methods, into the 892 
latently-infected Thy1.1 recipients or into naïve Thy1.1 mice. Latently-infected recipients were 893 
rested for 9-12 weeks, while the naïve recipients were rested for approximately 1.5 weeks. (B) 894 
Antibody depletion schedule. (C-E) The presence of tetramerpos donors was analyzed by flow 895 




independent experiments (n = 6 total). Three mice from each group were depleted 9 weeks after 897 
the transfer; three mice from each group were depleted 12 weeks after transfer. (C) Histograms 898 
of donor T cells within each individual recipient. (D) Representative FACS plots of tetramerpos 899 
donors immediately following the depletion regimen. (E) Frequency within each individual 900 
recipient of each analyzed tetramer as a percent of total donor CD8+ cells. TEFF recipients 3-6 are 901 
excluded because they did not have a donor population. (F) Tetramer staining was performed 11 902 
weeks after depletion in one experiment described above (n = 3).903 
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Supplemental Figure 1: Representative plots for repeat transfers and data from 1"
secondary stimulated OT-Is 2"
(A) Sorting strategy for isolating OT-I TM T cells after primary challenge. Briefly, 600 3"
naïve OT-I T cells expressing CD45.1 were transferred into naive B6 (CD45.2) recipients 4"
and challenged MCMV-SL8, (i.e. primary challenge). Thirteen weeks after the primary 5"
challenge, donor OT-I T cells were sorted using the CD45.1 marker and the TM subset 6"
was identified as CD27hi and KLRG1lo. (B) 6,000 sorted TM OT-I T cells were 7"
transferred into naïve B6 recipients and challenged with MCMV-SL8 (i.e. secondary 8"
challenge). Shown is the frequency and phenotype of blood-localized OT-Is over time, 9"
relative to total CD8pos T cells. Data was collected from two independent experiments 10"
(n=7 total). (C) Sorting strategy for isolating OT-I TM
 T cells after secondary challenge.  11"














































































































































Control Naïve Mice Post-Depletion (~5 Weeks Post Transfer) 
0 0.1 0.04 0 
Donor 
0 58 36 20 
7 Days Post-Challenge (~12 Weeks Post Transfer) 
Donor 
C
Supplemental Figure 2: Antibody depletion does not induce TM proliferation in 1"
naïve recipients. 2"
(A) Immediately prior to antibody depletion, the presence of donors in the blood was 3"
determined by flow cytometry. For TM and TEFF recipients, data was collected from two 4"
independent experiments (n=6 total). For naïve recipients, data was collected from one 5"
experiment (n=4 total) (B) Frequencies of total tetramer-binding CD8pos cells were 6"
determined in the blood of the chronically-infected Thy1.1 recipient mice prior to and 7"
immediately following the depletion scheduled in Figure 7B. Data"was"collected"from"8" two"independent"experiments"(n=6 total)"and"is"displayed"as"mean"±"SEM. (C) Age 9"
matched naïve Thy1.1 recipients received TM cells from a MCMV chronically-infected 10"
donor. Recipients were bled “pre-depletion” at 1.5 weeks post-transfer. Mice were started 11"
on the antibody depletion regimen immediately following the “pre-depletion” bleed and 12"
were bled again “post-depletion” at approximately 5 weeks post-transfer. A B6 mouse 13"
(Thy1.2pos) was used as the positive staining control. Naïve mice were challenged with 14"
MCMV approximately 12 weeks after the adoptive transfer. Data was collected from one 15"









































Gated on CD45.1 
Supplemental Figure 3: The KLRG1-specific antibody used for sorting does not 1"
deplete transferred cells. 2"
(A) CD45.1 splenocytes were stained with the anti-KLRG1 antibody (clone 2F1), mixed 3"
with unstained CD45.2 splenocytes in a 1:1 ratio and transferred into B6.CB17-Prkdcscid 4"
(SCID) mice from Jackson. The representative FACS plots show the KLRG1 stain of 5"
CD45.1pos, but not CD45.2pos cells (left) and the proportion of transferred cells that were 6"
CD45.1pos (right). (B) Six days after transfer, SCID recipients were bled and analyzed by 7"
flow cytometry. CD45.1pos cells were still a similar proportion of the transferred T cells 8"
(compare to A), suggesting that the large CD45.1pos KLRG1-stained population was not 9"
depleted. (C) Anti-KLRG1 staining six days after the transfer showed that there were still 10"
KLRG1hi CD45.1pos cells. As KLRG1 expression has been shown to be dependent on 11"
antigen stimulation, it is unlikely that the KLRG1hi cells were newly formed. Importantly, 12"
the CD45.1pos cells detected 6 days after transfer were no longer positive for the KLRG1 13"
antibody used prior to the transfer (not shown), suggesting that the cells have not been 14"













row_0 ANXA6 ANXA6 annexin	  A6 29 2.201579809 0.045963388 Yes T-­‐EFF	  biased
row_1 HMGB2 HMGB2 high-­‐mobility	  group	  box	  2 48 2.035401106 0.088924415 Yes Normalized	  Enrichment	  Score	  (NES) 2.1315544
row_2 ANXA4 ANXA4 annexin	  A4 59 1.94921422 0.13044995 Yes Nominal	  p-­‐value 0
row_3 GZMB GZMB granzyme	  B	  (granzyme	  2,	  cytotoxic	  T-­‐lymphocyte-­‐associated	  serine	  esterase	  1) 123 1.62263608 0.16212006 Yes FDR	  q-­‐value 0
row_4 CD244 CD244 CD244	  molecule,	  natural	  killer	  cell	  receptor	  2B4 153 1.540912032 0.19382909 Yes FWER	  p-­‐Value 0
row_5 CAPN2 CAPN2 calpain	  2,	  (m/II)	  large	  subunit 271 1.351189613 0.21678028 Yes
row_6 AP1S2 AP1S2 adaptor-­‐related	  protein	  complex	  1,	  sigma	  2	  subunit 332 1.288847923 0.24140769 Yes
row_7 LGALS1 LGALS1 lectin,	  galactoside-­‐binding,	  soluble,	  1	  (galectin	  1) 430 1.199626088 0.26214892 Yes
row_8 EBP EBP emopamil	  binding	  protein	  (sterol	  isomerase) 465 1.172553301 0.28564534 Yes
row_9 IKZF3 IKZF3 IKAROS	  family	  zinc	  finger	  3	  (Aiolos) 582 1.106175661 0.30336317 Yes
row_10 CA5B CA5B carbonic	  anhydrase	  VB,	  mitochondrial 710 1.037609816 0.3190186 Yes
row_11 SPN SPN sialophorin	  (leukosialin,	  CD43) 881 0.962003529 0.33076355 Yes
row_12 CX3CR1 CX3CR1 chemokine	  (C-­‐X3-­‐C	  motif)	  receptor	  1 939 0.938199341 0.34798452 Yes
row_13 SEP11 SEP11 septin	  11 970 0.926925778 0.3663934 Yes
row_14 STMN1 STMN1 stathmin	  1/oncoprotein	  18 1020 0.913609505 0.38350785 Yes
row_15 PYCARD PYCARD PYD	  and	  CARD	  domain	  containing 1208 0.852552652 0.39199024 Yes
row_16 NKG7 NKG7 natural	  killer	  cell	  group	  7	  sequence 1518 0.775441468 0.39234224 Yes
row_17 NSMAF NSMAF neutral	  sphingomyelinase	  (N-­‐SMase)	  activation	  associated	  factor 1534 0.772185385 0.40820757 Yes
row_18 SYTL2 SYTL2 synaptotagmin-­‐like	  2 1560 0.765723646 0.4234034 Yes
row_19 ZEB2 null null 1566 0.764536202 0.43963376 Yes
row_20 KLRG1 KLRG1 killer	  cell	  lectin-­‐like	  receptor	  subfamily	  G,	  member	  1 1857 0.708328545 0.43954486 Yes
row_21 CASP1 CASP1 caspase	  1,	  apoptosis-­‐related	  cysteine	  peptidase	  (interleukin	  1,	  beta,	  convertase) 2087 0.667113006 0.44180003 Yes
row_22 CRIPT CRIPT cysteine-­‐rich	  PDZ-­‐binding	  protein 2120 0.659288228 0.45432845 Yes
row_23 S1PR5 null null 2173 0.652283788 0.4656456 Yes
row_24 RAP2A RAP2A RAP2A,	  member	  of	  RAS	  oncogene	  family 2263 0.638532639 0.4747049 Yes
row_25 SUOX SUOX sulfite	  oxidase 2596 0.594230175 0.469928 Yes
row_26 NUF2 null null 2677 0.583921313 0.47828606 Yes
row_27 HIST1H2BN HIST1H2BN histone	  cluster	  1,	  H2bn 2817 0.562394679 0.48305234 Yes
row_28 RAB27A RAB27A RAB27A,	  member	  RAS	  oncogene	  family 3105 0.530466557 0.47928497 Yes
row_29 GZMA GZMA granzyme	  A	  (granzyme	  1,	  cytotoxic	  T-­‐lymphocyte-­‐associated	  serine	  esterase	  3) 3488 0.489474744 0.46959764 Yes
row_30 REEP5 REEP5 receptor	  accessory	  protein	  5 3539 0.485018671 0.477412 Yes
row_31 SYT11 SYT11 synaptotagmin	  XI 3719 0.466942877 0.4779986 Yes
row_32 GABARAPL2 GABARAPL2 GABA(A)	  receptor-­‐associated	  protein-­‐like	  2 3737 0.46474728 0.48712474 Yes
row_33 S100A4 S100A4 S100	  calcium	  binding	  protein	  A4 3739 0.464631855 0.49709648 Yes
row_34 SLAMF7 SLAMF7 SLAM	  family	  member	  7 3882 0.447826445 0.49923187 Yes
row_35 KLRC1 KLRC1 killer	  cell	  lectin-­‐like	  receptor	  subfamily	  C,	  member	  1 3929 0.443369746 0.50635964 Yes
row_36 DOCK5 DOCK5 dedicator	  of	  cytokinesis	  5 3976 0.438772231 0.51338816 Yes
row_37 CD48 CD48 CD48	  molecule 4013 0.435482979 0.5208758 Yes
row_38 GIMAP7 GIMAP7 GTPase,	  IMAP	  family	  member	  7 4790 0.363893896 0.48759487 No
row_39 FUT11 FUT11 fucosyltransferase	  11	  (alpha	  (1,3)	  fucosyltransferase) 4895 0.355715871 0.48975712 No
row_40 CENPE CENPE centromere	  protein	  E,	  312kDa 5014 0.345196247 0.49095032 No
row_41 KLRD1 KLRD1 killer	  cell	  lectin-­‐like	  receptor	  subfamily	  D,	  member	  1 5222 0.32846266 0.487065 No
row_42 RAP1GAP2 null null 5275 0.322605729 0.49126914 No
row_43 CYSLTR2 CYSLTR2 cysteinyl	  leukotriene	  receptor	  2 5287 0.321255773 0.4976174 No
row_44 ESM1 ESM1 endothelial	  cell-­‐specific	  molecule	  1 5351 0.316171378 0.50109965 No
row_45 FGL2 FGL2 fibrinogen-­‐like	  2 5635 0.294212759 0.49244696 No
row_46 PLEK PLEK pleckstrin 5828 0.278107136 0.48827025 No
row_47 KCNJ8 KCNJ8 potassium	  inwardly-­‐rectifying	  channel,	  subfamily	  J,	  member	  8 5934 0.270331919 0.48853728 No
row_48 NCAPG NCAPG non-­‐SMC	  condensin	  I	  complex,	  subunit	  G 6372 0.237775877 0.4705041 No
row_49 ST3GAL4 ST3GAL4 ST3	  beta-­‐galactoside	  alpha-­‐2,3-­‐sialyltransferase	  4 6538 0.227307007 0.4666625 No
row_50 INSL6 INSL6 insulin-­‐like	  6 7220 0.179024309 0.4344284 No
row_51 MYADM MYADM myeloid-­‐associated	  differentiation	  marker 7421 0.162519217 0.42733377 No
row_52 KIAA0101 KIAA0101 KIAA0101 7670 0.143709034 0.41728905 No
row_53 KLRK1 KLRK1 killer	  cell	  lectin-­‐like	  receptor	  subfamily	  K,	  member	  1 8076 0.112943329 0.3982587 No
row_54 RUNX1 RUNX1 runt-­‐related	  transcription	  factor	  1	  (acute	  myeloid	  leukemia	  1;	  aml1	  oncogene) 8205 0.104097836 0.39371997 No
row_55 CSPP1 CSPP1 centrosome	  and	  spindle	  pole	  associated	  protein	  1 8271 0.099030837 0.3924113 No
Supplemental	  Table	  1A:	  Transcripts	  UP	  in	  TEFF	  relative	  to	  TM
2row_56 TAF9B TAF9B TAF9B	  RNA	  polymerase	  II,	  TATA	  box	  binding	  protein	  (TBP)-­‐associated	  factor,	  31kDa 8535 0.080059439 0.38019818 No
row_57 NUSAP1 NUSAP1 nucleolar	  and	  spindle	  associated	  protein	  1 8559 0.078409061 0.3806708 No
row_58 ANXA1 ANXA1 annexin	  A1 8977 0.046614461 0.35957327 No
row_59 GPX8 null null 9050 0.042167794 0.35666668 No
row_60 ANXA2 ANXA2 annexin	  A2 9161 0.033796653 0.35156527 No
row_61 KIF11 KIF11 kinesin	  family	  member	  11 9239 0.028000101 0.348088 No
row_62 CASC5 CASC5 cancer	  susceptibility	  candidate	  5 10134 -­‐0.028975241 0.3013263 No T-­‐MEM	  biased
row_63 HIST1H2BI HIST1H2BI histone	  cluster	  1,	  H2bi 10379 -­‐0.047193091 0.28941122 No
row_64 PRDM1 PRDM1 PR	  domain	  containing	  1,	  with	  ZNF	  domain 10943 -­‐0.087488279 0.2614568 No
row_65 RAB5B RAB5B RAB5B,	  member	  RAS	  oncogene	  family 11206 -­‐0.106175564 0.24986018 No
row_66 SPC25 null null 11582 -­‐0.130460307 0.23279792 No
row_67 S100A10 S100A10 S100	  calcium	  binding	  protein	  A10 11678 -­‐0.136860937 0.23071527 No
row_68 SYTL3 SYTL3 synaptotagmin-­‐like	  3 12076 -­‐0.165555894 0.21324411 No
row_69 AS3MT AS3MT arsenic	  (+3	  oxidation	  state)	  methyltransferase 12183 -­‐0.173790261 0.21137518 No
row_70 APOBEC2 APOBEC2 apolipoprotein	  B	  mRNA	  editing	  enzyme,	  catalytic	  polypeptide-­‐like	  2 13491 -­‐0.275097936 0.14803253 No
row_71 RPA3 RPA3 replication	  protein	  A3,	  14kDa 13828 -­‐0.302330554 0.13674569 No
row_72 OSBPL3 OSBPL3 oxysterol	  binding	  protein-­‐like	  3 14911 -­‐0.398935348 0.08800114 No
row_73 MKI67 MKI67 antigen	  identified	  by	  monoclonal	  antibody	  Ki-­‐67 15923 -­‐0.497105926 0.04513806 No
row_74 MXI1 MXI1 MAX	  interactor	  1 16098 -­‐0.51361376 0.04699668 No
row_75 IL18RAP IL18RAP interleukin	  18	  receptor	  accessory	  protein 17706 -­‐0.753345549 -­‐0.02192908 No
row_76 PRC1 PRC1 protein	  regulator	  of	  cytokinesis	  1 17790 -­‐0.772486866 -­‐0.009661613 No
row_77 CCNA2 CCNA2 cyclin	  A2 17875 -­‐0.79208225 0.002975634 No
row_78 GZMK GZMK granzyme	  K	  (granzyme	  3;	  tryptase	  II) 18643 -­‐1.195715308 -­‐0.011881162 No












row_0 PHPT1 PHPT1 phosphohistidine	  phosphatase	  1 37 2.124774694 0.026149271 No T-­‐EFF	  biased
row_1 HSPB11 null null 290 1.328898907 0.030335644 No Normalized	  Enrichment	  Score	  (NES) -­‐1.6801751
row_2 LSM7 LSM7 LSM7	  homolog,	  U6	  small	  nuclear	  RNA	  associated	  (S.	  cerevisiae) 329 1.291045427 0.045399252 No Nominal	  p-­‐value 0.00777202
row_3 IFI27L2 null null 592 1.101828933 0.04604919 No FDR	  q-­‐value 8.90E-­‐04
row_4 RTP4 RTP4 receptor	  transporter	  protein	  4 600 1.096092939 0.060181282 No FWER	  p-­‐Value 0.003
row_5 MED4 MED4 mediator	  of	  RNA	  polymerase	  II	  transcription,	  subunit	  4	  homolog	  (S.	  cerevisiae) 842 0.978564978 0.06031665 No
row_6 RPS29 RPS29 ribosomal	  protein	  S29 901 0.955645084 0.06987862 No
row_7 RAPGEF4 RAPGEF4 Rap	  guanine	  nucleotide	  exchange	  factor	  (GEF)	  4 1484 0.782799721 0.049292903 No
row_8 CYB5A CYB5A cytochrome	  b5	  type	  A	  (microsomal) 1502 0.778091848 0.05868529 No
row_9 MRPS5 MRPS5 mitochondrial	  ribosomal	  protein	  S5 2032 0.676983833 0.03951729 No
row_10 PIP4K2A null null 2133 0.656981051 0.04289404 No
row_11 APEX1 APEX1 APEX	  nuclease	  (multifunctional	  DNA	  repair	  enzyme)	  1 2262 0.638559878 0.0445383 No
row_12 QSER1 QSER1 glutamine	  and	  serine	  rich	  1 2270 0.637303054 0.052599363 No
row_13 SH3BP5 SH3BP5 SH3-­‐domain	  binding	  protein	  5	  (BTK-­‐associated) 2576 0.596591115 0.044277374 No
row_14 PDK1 PDK1 pyruvate	  dehydrogenase	  kinase,	  isozyme	  1 2753 0.571303666 0.042479545 No
row_15 SEPP1 SEPP1 selenoprotein	  P,	  plasma,	  1 2844 0.559307992 0.045095507 No
row_16 STAMBPL1 STAMBPL1 STAM	  binding	  protein-­‐like	  1 3096 0.531519473 0.03878356 No
row_17 ITGAE ITGAE integrin,	  alpha	  E	  (antigen	  CD103,	  human	  mucosal	  lymphocyte	  antigen	  1;	  alpha	  polypeptide) 3106 0.530423522 0.04532398 No
row_18 TLR1 TLR1 toll-­‐like	  receptor	  1 3210 0.518464327 0.046708275 No
row_19 ZNF761 ZNF761 zinc	  finger	  protein	  761 3302 0.50811398 0.04859363 No
row_20 F2RL1 F2RL1 coagulation	  factor	  II	  (thrombin)	  receptor-­‐like	  1 3342 0.504218102 0.053192213 No
row_21 NAT1 NAT1 N-­‐acetyltransferase	  1	  (arylamine	  N-­‐acetyltransferase) 3507 0.488090605 0.05093128 No
row_22 DAPL1 DAPL1 death	  associated	  protein-­‐like	  1 3673 0.47194767 0.04840356 No
row_23 HINT3 HINT3 histidine	  triad	  nucleotide	  binding	  protein	  3 3834 0.453408092 0.04589636 No
row_24 LTV1 LTV1 LTV1	  homolog	  (S.	  cerevisiae) 4081 0.428189248 0.03848292 No
row_25 IMPDH2 IMPDH2 IMP	  (inosine	  monophosphate)	  dehydrogenase	  2 4847 0.359094143 0.002560527 No
row_26 DUSP10 DUSP10 dual	  specificity	  phosphatase	  10 4855 0.35811159 0.00692713 No
row_27 RRP15 null null 4880 0.356415987 0.010367425 No
row_28 XCL1 XCL1 chemokine	  (C	  motif)	  ligand	  1 5056 0.342206746 0.005591196 No
row_29 BCL9 BCL9 B-­‐cell	  CLL/lymphoma	  9 5238 0.326921731 2.94E-­‐04 No
row_30 PRDX6 PRDX6 peroxiredoxin	  6 5248 0.325534701 0.004122876 No
row_31 CD3D CD3D CD3d	  molecule,	  delta	  (CD3-­‐TCR	  complex) 5438 0.309563071 -­‐0.001829683 No
row_32 TOX TOX -­‐ 5553 0.300573617 -­‐0.003913531 No
row_33 DKC1 DKC1 dyskeratosis	  congenita	  1,	  dyskerin 5581 0.298592925 -­‐0.001397898 No
row_34 RPS19 RPS19 ribosomal	  protein	  S19 5641 0.293431848 -­‐6.52E-­‐04 No
row_35 RPLP1 RPLP1 ribosomal	  protein,	  large,	  P1 5781 0.281639785 -­‐0.004315579 No
row_36 CCDC91 CCDC91 coiled-­‐coil	  domain	  containing	  91 5822 0.278348088 -­‐0.002759035 No
row_37 SLFN5 SLFN5 schlafen	  family	  member	  5 5899 0.273217082 -­‐0.003184468 No
row_38 FBL FBL fibrillarin 5910 0.27217257 -­‐1.15E-­‐04 No
row_39 TMLHE TMLHE trimethyllysine	  hydroxylase,	  epsilon 6244 0.246418536 -­‐0.014559025 No
row_40 IFT80 IFT80 intraflagellar	  transport	  80	  homolog	  (Chlamydomonas) 6313 0.242544681 -­‐0.014964985 No
row_41 LY6E LY6E lymphocyte	  antigen	  6	  complex,	  locus	  E 6424 0.234440193 -­‐0.017711282 No
row_42 ATP1B1 ATP1B1 ATPase,	  Na+/K+	  transporting,	  beta	  1	  polypeptide 6548 0.226953819 -­‐0.02124784 No
row_43 TTC27 TTC27 tetratricopeptide	  repeat	  domain	  27 7498 0.156670496 -­‐0.06963192 No
row_44 USP28 USP28 ubiquitin	  specific	  peptidase	  28 7576 0.150735766 -­‐0.07173128 No
row_45 ACTN1 ACTN1 actinin,	  alpha	  1 7597 0.148684606 -­‐0.07082716 No
row_46 SSBP2 SSBP2 single-­‐stranded	  DNA	  binding	  protein	  2 7678 0.14299418 -­‐0.07318846 No
row_47 HRSP12 HRSP12 heat-­‐responsive	  protein	  12 7680 0.142702043 -­‐0.0713533 No
row_48 SLAMF6 SLAMF6 SLAM	  family	  member	  6 7685 0.142558053 -­‐0.06967954 No
row_49 RPL29 RPL29 ribosomal	  protein	  L29 7738 0.138756722 -­‐0.0706082 No
row_50 RPL14 RPL14 ribosomal	  protein	  L14 7785 0.135675624 -­‐0.07125861 No
row_51 RRAS2 RRAS2 related	  RAS	  viral	  (r-­‐ras)	  oncogene	  homolog	  2 7850 0.130808711 -­‐0.07293046 No
row_52 KBTBD11 KBTBD11 kelch	  repeat	  and	  BTB	  (POZ)	  domain	  containing	  11 7905 0.126582831 -­‐0.07412655 No
row_53 RPL10A RPL10A ribosomal	  protein	  L10a 7936 0.123617478 -­‐0.074085824 No
row_54 LZTFL1 LZTFL1 leucine	  zipper	  transcription	  factor-­‐like	  1 8371 0.092378221 -­‐0.0959387 No
row_55 TTC3 TTC3 tetratricopeptide	  repeat	  domain	  3 8384 0.091630973 -­‐0.0953642 No
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4row_56 RPS26 RPS26 ribosomal	  protein	  S26 8636 0.072893247 -­‐0.10774501 No
row_57 KLHDC1 KLHDC1 kelch	  domain	  containing	  1 8877 0.055129666 -­‐0.11977602 No
row_58 HMP19 HMP19 -­‐ 9065 0.040402696 -­‐0.12918396 No
row_59 BZW2 BZW2 basic	  leucine	  zipper	  and	  W2	  domains	  2 9068 0.040138628 -­‐0.12875916 No
row_60 GID4 null null 9096 0.038265821 -­‐0.12968835 No
row_61 CHURC1 CHURC1 churchill	  domain	  containing	  1 9274 0.025683668 -­‐0.13875937 No
row_62 KIAA1033 KIAA1033 KIAA1033 9314 0.022567095 -­‐0.14053434 No
row_63 MRPL23 MRPL23 mitochondrial	  ribosomal	  protein	  L23 9397 0.016983615 -­‐0.14466944 No
row_64 EGR2 EGR2 early	  growth	  response	  2	  (Krox-­‐20	  homolog,	  Drosophila) 10037 -­‐0.020757651 -­‐0.17836967 No T-­‐MEM	  biased
row_65 LPHN2 LPHN2 latrophilin	  2 10097 -­‐0.025689999 -­‐0.1811667 No
row_66 XKRX XKRX XK,	  Kell	  blood	  group	  complex	  subunit-­‐related,	  X-­‐linked 10256 -­‐0.038267016 -­‐0.18906099 No
row_67 LCLAT1 null null 10373 -­‐0.04668713 -­‐0.19461079 No
row_68 INSR INSR insulin	  receptor 10396 -­‐0.048602778 -­‐0.19513735 No
row_69 RPL8 RPL8 ribosomal	  protein	  L8 10560 -­‐0.059909303 -­‐0.20301111 No
row_70 GPATCH4 null null 10752 -­‐0.074455388 -­‐0.21218112 No
row_71 TRIB2 TRIB2 tribbles	  homolog	  2	  (Drosophila) 11027 -­‐0.093001895 -­‐0.22551872 No
row_72 RPL18 RPL18 ribosomal	  protein	  L18 11234 -­‐0.108678244 -­‐0.23503341 No
row_73 TRIM13 TRIM13 tripartite	  motif-­‐containing	  13 11801 -­‐0.14649047 -­‐0.2631885 No
row_74 LYPD6B null null 11911 -­‐0.15424104 -­‐0.2669429 No
row_75 MGST2 MGST2 microsomal	  glutathione	  S-­‐transferase	  2 11950 -­‐0.156489357 -­‐0.26689252 No
row_76 ACSL3 ACSL3 acyl-­‐CoA	  synthetase	  long-­‐chain	  family	  member	  3 12373 -­‐0.187292844 -­‐0.2868514 No
row_77 DPP4 DPP4 dipeptidyl-­‐peptidase	  4	  (CD26,	  adenosine	  deaminase	  complexing	  protein	  2) 12434 -­‐0.19199796 -­‐0.2875009 No
row_78 ZBTB10 ZBTB10 zinc	  finger	  and	  BTB	  domain	  containing	  10 12514 -­‐0.198208988 -­‐0.28907838 No
row_79 NEDD4L NEDD4L neural	  precursor	  cell	  expressed,	  developmentally	  down-­‐regulated	  4-­‐like 12830 -­‐0.22265242 -­‐0.3028803 No
row_80 EPHX1 EPHX1 epoxide	  hydrolase	  1,	  microsomal	  (xenobiotic) 12871 -­‐0.225831643 -­‐0.30201867 No
row_81 MYC MYC v-­‐myc	  myelocytomatosis	  viral	  oncogene	  homolog	  (avian) 12915 -­‐0.229761392 -­‐0.30126455 No
row_82 TSPAN13 TSPAN13 tetraspanin	  13 12940 -­‐0.232248098 -­‐0.29946736 No
row_83 EEF1B2 EEF1B2 eukaryotic	  translation	  elongation	  factor	  1	  beta	  2 13130 -­‐0.247839764 -­‐0.30623668 No
row_84 TFRC TFRC transferrin	  receptor	  (p90,	  CD71) 13593 -­‐0.283705652 -­‐0.32704648 No
row_85 P2RY10 P2RY10 purinergic	  receptor	  P2Y,	  G-­‐protein	  coupled,	  10 13647 -­‐0.288299233 -­‐0.32604948 No
row_86 LEF1 LEF1 lymphoid	  enhancer-­‐binding	  factor	  1 13701 -­‐0.291425049 -­‐0.32501107 No
row_87 IFNGR2 IFNGR2 interferon	  gamma	  receptor	  2	  (interferon	  gamma	  transducer	  1) 13751 -­‐0.295711279 -­‐0.3237033 No
row_88 SPRED2 SPRED2 sprouty-­‐related,	  EVH1	  domain	  containing	  2 13872 -­‐0.30734697 -­‐0.32601652 No
row_89 TNFSF8 TNFSF8 tumor	  necrosis	  factor	  (ligand)	  superfamily,	  member	  8 13970 -­‐0.315796912 -­‐0.32699504 No
row_90 CMSS1 null null 13996 -­‐0.318091691 -­‐0.32411507 No
row_91 PECAM1 PECAM1 platelet/endothelial	  cell	  adhesion	  molecule	  (CD31	  antigen) 14002 -­‐0.318354994 -­‐0.3201682 No
row_92 MYB MYB v-­‐myb	  myeloblastosis	  viral	  oncogene	  homolog	  (avian) 14205 -­‐0.335532546 -­‐0.32646832 No
row_93 JUN JUN jun	  oncogene 14239 -­‐0.338070452 -­‐0.3237493 No
row_94 RPL13 RPL13 ribosomal	  protein	  L13 14346 -­‐0.346955091 -­‐0.32479405 No
row_95 RPS2 RPS2 ribosomal	  protein	  S2 14452 -­‐0.356475323 -­‐0.32565963 No
row_96 PCGF5 PCGF5 polycomb	  group	  ring	  finger	  5 14522 -­‐0.362784624 -­‐0.32452768 No
row_97 CNGA1 CNGA1 cyclic	  nucleotide	  gated	  channel	  alpha	  1 14723 -­‐0.381109834 -­‐0.33011833 No
row_98 GRIA3 GRIA3 glutamate	  receptor,	  ionotrophic,	  AMPA	  3 14748 -­‐0.382496178 -­‐0.32633293 No
row_99 DPH5 DPH5 DPH5	  homolog	  (S.	  cerevisiae) 14846 -­‐0.391592532 -­‐0.32630846 No
row_100 RGS10 RGS10 regulator	  of	  G-­‐protein	  signalling	  10 15259 -­‐0.433039695 -­‐0.34248376 No
row_101 EMB EMB embigin	  homolog	  (mouse) 15436 -­‐0.449893624 -­‐0.34588817 No
row_102 SELL SELL selectin	  L	  (lymphocyte	  adhesion	  molecule	  1) 15556 -­‐0.460011512 -­‐0.34612808 No
row_103 RPS5 RPS5 ribosomal	  protein	  S5 15705 -­‐0.475598007 -­‐0.3477036 No
row_104 RPL15 RPL15 ribosomal	  protein	  L15 15770 -­‐0.480787158 -­‐0.3447443 No
row_105 INPP4B INPP4B inositol	  polyphosphate-­‐4-­‐phosphatase,	  type	  II,	  105kDa 15848 -­‐0.489236385 -­‐0.34236437 No
row_106 BTF3L4 BTF3L4 basic	  transcription	  factor	  3-­‐like	  4 15895 -­‐0.494006366 -­‐0.3382731 No
row_107 IL6ST IL6ST interleukin	  6	  signal	  transducer	  (gp130,	  oncostatin	  M	  receptor) 16084 -­‐0.512494206 -­‐0.34148717 No
row_108 WDR12 WDR12 WD	  repeat	  domain	  12 16295 -­‐0.535118759 -­‐0.34557158 No
row_109 RPL28 RPL28 ribosomal	  protein	  L28 16305 -­‐0.537068784 -­‐0.3389432 No
row_110 ST6GAL1 ST6GAL1 ST6	  beta-­‐galactosamide	  alpha-­‐2,6-­‐sialyltranferase	  1 16420 -­‐0.552493393 -­‐0.33769348 No
row_111 ITGA6 ITGA6 integrin,	  alpha	  6 16596 -­‐0.574453831 -­‐0.33939645 No
row_112 RPLP0 RPLP0 ribosomal	  protein,	  large,	  P0 16715 -­‐0.589519203 -­‐0.33786944 No
row_113 PELI1 PELI1 pellino	  homolog	  1	  (Drosophila) 17138 -­‐0.650897205 -­‐0.35169357 No
row_114 SATB1 SATB1 special	  AT-­‐rich	  sequence	  binding	  protein	  1	  (binds	  to	  nuclear	  matrix/scaffold-­‐associating	  DNA's) 17264 -­‐0.669767857 -­‐0.34947684 No
row_115 RPSA RPSA ribosomal	  protein	  SA 17448 -­‐0.702700913 -­‐0.3499081 No
row_116 PPIC PPIC peptidylprolyl	  isomerase	  C	  (cyclophilin	  C) 17721 -­‐0.756398022 -­‐0.35436085 Yes
row_117 DGKA DGKA diacylglycerol	  kinase,	  alpha	  80kDa 17727 -­‐0.758206606 -­‐0.34459355 Yes
5row_118 CD69 CD69 CD69	  molecule 17870 -­‐0.790673494 -­‐0.3416808 Yes
row_119 ST8SIA1 ST8SIA1 ST8	  alpha-­‐N-­‐acetyl-­‐neuraminide	  alpha-­‐2,8-­‐sialyltransferase	  1 17913 -­‐0.802390575 -­‐0.3332961 Yes
row_120 CCR9 CCR9 chemokine	  (C-­‐C	  motif)	  receptor	  9 18031 -­‐0.836443365 -­‐0.32844844 Yes
row_121 HOOK1 HOOK1 hook	  homolog	  1	  (Drosophila) 18237 -­‐0.906686187 -­‐0.32735014 Yes
row_122 RAB3IP RAB3IP RAB3A	  interacting	  protein	  (rabin3) 18248 -­‐0.911961794 -­‐0.3158141 Yes
row_123 TCP11L2 TCP11L2 t-­‐complex	  11	  (mouse)	  like	  2 18438 -­‐1.008909702 -­‐0.31251243 Yes
row_124 PDE3B PDE3B phosphodiesterase	  3B,	  cGMP-­‐inhibited 18484 -­‐1.036287308 -­‐0.30119213 Yes
row_125 CD2AP CD2AP CD2-­‐associated	  protein 18520 -­‐1.068836212 -­‐0.28890944 Yes
row_126 ICOS ICOS inducible	  T-­‐cell	  co-­‐stimulator 18674 -­‐1.228775859 -­‐0.28078425 Yes
row_127 CD27 null null 18716 -­‐1.286845565 -­‐0.26593572 Yes
row_128 ZEB1 null null 18771 -­‐1.377133369 -­‐0.25058365 Yes
row_129 TCF7 TCF7 transcription	  factor	  7	  (T-­‐cell	  specific,	  HMG-­‐box) 18790 -­‐1.420588374 -­‐0.23274246 Yes
row_130 SH3PXD2A SH3PXD2A SH3	  and	  PX	  domains	  2A 18808 -­‐1.47138989 -­‐0.21417587 Yes
row_131 RPS9 RPS9 ribosomal	  protein	  S9 18857 -­‐1.63666749 -­‐0.19507043 Yes
row_132 LTB LTB lymphotoxin	  beta	  (TNF	  superfamily,	  member	  3) 18891 -­‐1.829720855 -­‐0.17261285 Yes
row_133 SESN3 SESN3 sestrin	  3 18900 -­‐1.950626612 -­‐0.14722613 Yes
row_134 CCR7 CCR7 chemokine	  (C-­‐C	  motif)	  receptor	  7 18917 -­‐2.157334805 -­‐0.11952945 Yes
row_135 IL7R IL7R interleukin	  7	  receptor 18927 -­‐2.443236351 -­‐0.087677345 Yes
row_136 TRAT1 TRAT1 T	  cell	  receptor	  associated	  transmembrane	  adaptor	  1 18943 -­‐2.915472031 -­‐0.04989529 Yes












row_0 ITGB1 ITGB1 integrin,	  beta	  1	  (fibronectin	  receptor,	  beta	  polypeptide,	  antigen	  CD29	  includes	  MDF2,	  MSK12) 5 4.547115803 0.019984426 Yes T-­‐EFF	  biased
row_1 TBX21 TBX21 T-­‐box	  21 12 4.094614983 0.037900336 Yes Normalized	  Enrichment	  Score	  (NES) 2.6822367
row_2 S1PR5 null null 22 3.814461708 0.054408733 Yes Nominal	  p-­‐value 0
row_3 GZMB GZMB granzyme	  B	  (granzyme	  2,	  cytotoxic	  T-­‐lymphocyte-­‐associated	  serine	  esterase	  1) 23 3.791385651 0.07129387 Yes FDR	  q-­‐value 0
row_4 SAMD3 SAMD3 sterile	  alpha	  motif	  domain	  containing	  3 25 3.75134635 0.08794741 Yes FWER	  p-­‐Value 0
row_5 GNPTAB GNPTAB N-­‐acetylglucosamine-­‐1-­‐phosphate	  transferase,	  alpha	  and	  beta	  subunits 45 3.55580759 0.10277109 Yes
row_6 GOLIM4 null null 57 3.421685934 0.117423676 Yes
row_7 FASLG FASLG Fas	  ligand	  (TNF	  superfamily,	  member	  6) 63 3.370791435 0.13216928 Yes
row_8 CHSY1 CHSY1 carbohydrate	  (chondroitin)	  synthase	  1 64 3.352074385 0.14709792 Yes
row_9 GZMA GZMA granzyme	  A	  (granzyme	  1,	  cytotoxic	  T-­‐lymphocyte-­‐associated	  serine	  esterase	  3) 67 3.331688643 0.16182922 Yes
row_10 CAMK2N1 CAMK2N1 calcium/calmodulin-­‐dependent	  protein	  kinase	  II	  inhibitor	  1 84 3.213935375 0.17529018 Yes
row_11 MYO1F MYO1F myosin	  IF 88 3.202200413 0.18939151 Yes
row_12 RAB8B RAB8B RAB8B,	  member	  RAS	  oncogene	  family 105 3.118102789 0.20242569 Yes
row_13 LGALS1 LGALS1 lectin,	  galactoside-­‐binding,	  soluble,	  1	  (galectin	  1) 134 2.969976187 0.2141608 Yes
row_14 CCL5 CCL5 chemokine	  (C-­‐C	  motif)	  ligand	  5 152 2.908002853 0.226206 Yes
row_15 BHLHE40 null null 161 2.877945662 0.23859686 Yes
row_16 ITGAL ITGAL integrin,	  alpha	  L	  (antigen	  CD11A	  (p180),	  lymphocyte	  function-­‐associated	  antigen	  1;	  alpha	  polypeptide) 162 2.873387337 0.25139365 Yes
row_17 FAM49A FAM49A family	  with	  sequence	  similarity	  49,	  member	  A 164 2.851606131 0.26404014 Yes
row_18 ITGB2 ITGB2 integrin,	  beta	  2	  (complement	  component	  3	  receptor	  3	  and	  4	  subunit) 169 2.844150066 0.2764936 Yes
row_19 CHST11 CHST11 carbohydrate	  (chondroitin	  4)	  sulfotransferase	  11 186 2.792424679 0.28807735 Yes
row_20 CD244 CD244 CD244	  molecule,	  natural	  killer	  cell	  receptor	  2B4 187 2.791054487 0.30050746 Yes
row_21 ZEB2 null null 188 2.790454865 0.3129349 Yes
row_22 CASP4 CASP4 caspase	  4,	  apoptosis-­‐related	  cysteine	  peptidase 197 2.750204802 0.32475683 Yes
row_23 CCL4 CCL4 chemokine	  (C-­‐C	  motif)	  ligand	  4 203 2.743010283 0.33670658 Yes
row_24 F2R F2R coagulation	  factor	  II	  (thrombin)	  receptor 209 2.721811771 0.3485619 Yes
row_25 IQGAP2 IQGAP2 IQ	  motif	  containing	  GTPase	  activating	  protein	  2 213 2.718414068 0.36050868 Yes
row_26 CX3CR1 CX3CR1 chemokine	  (C-­‐X3-­‐C	  motif)	  receptor	  1 227 2.690318346 0.37179753 Yes
row_27 FYN FYN FYN	  oncogene	  related	  to	  SRC,	  FGR,	  YES 232 2.68144393 0.38352638 Yes
row_28 PRDM1 PRDM1 PR	  domain	  containing	  1,	  with	  ZNF	  domain 246 2.635905027 0.39457288 Yes
row_29 KLRG1 KLRG1 killer	  cell	  lectin-­‐like	  receptor	  subfamily	  G,	  member	  1 284 2.517981768 0.4038155 Yes
row_30 NKG7 NKG7 natural	  killer	  cell	  group	  7	  sequence 315 2.45875144 0.41316733 Yes
row_31 ANXA2 ANXA2 annexin	  A2 326 2.432535887 0.42346796 Yes
row_32 HOPX null null 344 2.38733077 0.4331943 Yes
row_33 GOLM1 null null 357 2.348069429 0.4430122 Yes
row_34 IFNG IFNG interferon,	  gamma 394 2.25906682 0.45115504 Yes
row_35 CXCR3 CXCR3 chemokine	  (C-­‐X-­‐C	  motif)	  receptor	  3 404 2.241060257 0.4606562 Yes
row_36 IL18RAP IL18RAP interleukin	  18	  receptor	  accessory	  protein 430 2.17173934 0.46899617 Yes
row_37 GGH GGH gamma-­‐glutamyl	  hydrolase	  (conjugase,	  folylpolygammaglutamyl	  hydrolase) 453 2.1221416 0.4772751 Yes
row_38 IL10RA IL10RA interleukin	  10	  receptor,	  alpha 484 2.0806427 0.48494297 Yes
row_39 S100A4 S100A4 S100	  calcium	  binding	  protein	  A4 493 2.068409681 0.49372852 Yes
row_40 ATP2B4 ATP2B4 ATPase,	  Ca++	  transporting,	  plasma	  membrane	  4 599 1.917457938 0.49667367 Yes
row_41 ANXA4 ANXA4 annexin	  A4 605 1.91564846 0.5049387 Yes
row_42 CMKLR1 CMKLR1 chemokine-­‐like	  receptor	  1 621 1.891701698 0.51256436 Yes
row_43 SYT11 SYT11 synaptotagmin	  XI 665 1.837343931 0.51845604 Yes
row_44 HMGB2 HMGB2 high-­‐mobility	  group	  box	  2 679 1.822000504 0.5258778 Yes
row_45 DSTN DSTN destrin	  (actin	  depolymerizing	  factor) 697 1.800909758 0.5329925 Yes
row_46 CDC42EP3 CDC42EP3 CDC42	  effector	  protein	  (Rho	  GTPase	  binding)	  3 707 1.787336588 0.540473 Yes
row_47 SLAMF7 SLAMF7 SLAM	  family	  member	  7 736 1.758211851 0.5468114 Yes
row_48 SLC20A1 SLC20A1 solute	  carrier	  family	  20	  (phosphate	  transporter),	  member	  1 747 1.752829194 0.55408496 Yes
row_49 CAPN2 CAPN2 calpain	  2,	  (m/II)	  large	  subunit 760 1.739896894 0.5611943 Yes
row_50 KLRC1 KLRC1 killer	  cell	  lectin-­‐like	  receptor	  subfamily	  C,	  member	  1 829 1.675436616 0.56503296 Yes
row_51 SNX10 SNX10 sorting	  nexin	  10 831 1.672691703 0.5724291 Yes
row_52 CASP1 CASP1 caspase	  1,	  apoptosis-­‐related	  cysteine	  peptidase	  (interleukin	  1,	  beta,	  convertase) 870 1.62736547 0.57765204 Yes
row_53 SYTL2 SYTL2 synaptotagmin-­‐like	  2 912 1.590363145 0.5825504 Yes
row_54 IL18R1 IL18R1 interleukin	  18	  receptor	  1 914 1.5899297 0.5895779 Yes
row_55 TNF TNF tumor	  necrosis	  factor	  (TNF	  superfamily,	  member	  2) 1030 1.50204432 0.5901402 Yes
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7row_56 REEP5 REEP5 receptor	  accessory	  protein	  5 1047 1.485551 0.59590375 Yes
row_57 AHNAK AHNAK AHNAK	  nucleoprotein	  (desmoyokin) 1089 1.449422479 0.60017437 Yes
row_58 PLEK PLEK pleckstrin 1103 1.443816662 0.60591185 Yes
row_59 KLRD1 KLRD1 killer	  cell	  lectin-­‐like	  receptor	  subfamily	  D,	  member	  1 1105 1.442571759 0.6122832 Yes
row_60 S100A6 S100A6 S100	  calcium	  binding	  protein	  A6 1113 1.434784532 0.6183001 Yes
row_61 SYTL3 SYTL3 synaptotagmin-­‐like	  3 1125 1.42879796 0.62407726 Yes
row_62 IKZF3 IKZF3 IKAROS	  family	  zinc	  finger	  3	  (Aiolos) 1128 1.427701592 0.630329 Yes
row_63 SLC4A7 SLC4A7 solute	  carrier	  family	  4,	  sodium	  bicarbonate	  cotransporter,	  member	  7 1178 1.401299 0.6339591 Yes
row_64 PTPRJ PTPRJ protein	  tyrosine	  phosphatase,	  receptor	  type,	  J 1214 1.369297743 0.6381926 Yes
row_65 ITGA4 ITGA4 integrin,	  alpha	  4	  (antigen	  CD49D,	  alpha	  4	  subunit	  of	  VLA-­‐4	  receptor) 1215 1.368969679 0.6442894 Yes
row_66 NSMAF NSMAF neutral	  sphingomyelinase	  (N-­‐SMase)	  activation	  associated	  factor 1243 1.353946567 0.64888066 Yes
row_67 PTMS PTMS parathymosin 1245 1.353373647 0.6548547 Yes
row_68 LMNB1 LMNB1 lamin	  B1 1263 1.344273448 0.6599358 Yes
row_69 SLC25A24 SLC25A24 solute	  carrier	  family	  25	  (mitochondrial	  carrier;	  phosphate	  carrier),	  member	  24 1309 1.323735595 0.66343355 Yes
row_70 FAM3B FAM3B family	  with	  sequence	  similarity	  3,	  member	  B 1320 1.320166111 0.66878015 Yes
row_71 ATP2B1 ATP2B1 ATPase,	  Ca++	  transporting,	  plasma	  membrane	  1 1338 1.308222771 0.67370063 Yes
row_72 RAP2A RAP2A RAP2A,	  member	  of	  RAS	  oncogene	  family 1345 1.304151654 0.6791891 Yes
row_73 CENPE CENPE centromere	  protein	  E,	  312kDa 1574 1.186092257 0.6723237 Yes
row_74 FCHO2 FCHO2 FCH	  domain	  only	  2 1591 1.179958582 0.6767263 Yes
row_75 ANXA1 ANXA1 annexin	  A1 1668 1.140519023 0.67775637 Yes
row_76 PPP1R12A PPP1R12A protein	  phosphatase	  1,	  regulatory	  (inhibitor)	  subunit	  12A 1761 1.099994302 0.67775357 Yes
row_77 SPN SPN sialophorin	  (leukosialin,	  CD43) 1801 1.082511306 0.6804967 Yes
row_78 AIM1 AIM1 absent	  in	  melanoma	  1 2012 1.000916958 0.67376566 Yes
row_79 CTSD CTSD cathepsin	  D	  (lysosomal	  aspartyl	  peptidase) 2037 0.994105399 0.6769143 Yes
row_80 ID2 ID2 inhibitor	  of	  DNA	  binding	  2,	  dominant	  negative	  helix-­‐loop-­‐helix	  protein 2052 0.98960793 0.68057567 Yes
row_81 DOCK5 DOCK5 dedicator	  of	  cytokinesis	  5 2061 0.986442983 0.6845426 Yes
row_82 RORA RORA RAR-­‐related	  orphan	  receptor	  A 2125 0.963672876 0.68547773 Yes
row_83 ARSB ARSB arylsulfatase	  B 2225 0.930148363 0.68434554 Yes
row_84 RAP1GAP2 null null 2273 0.917509854 0.6859276 Yes
row_85 OSBPL3 OSBPL3 oxysterol	  binding	  protein-­‐like	  3 2337 0.898226559 0.6865713 Yes
row_86 SEP11 SEP11 septin	  11 2657 0.81385839 0.6731998 No
row_87 SLC9A7 SLC9A7 solute	  carrier	  family	  9	  (sodium/hydrogen	  exchanger),	  member	  7 2683 0.806290448 0.67545867 No
row_88 S100A10 S100A10 S100	  calcium	  binding	  protein	  A10 2710 0.799574256 0.6776343 No
row_89 PRR13 PRR13 proline	  rich	  13 2811 0.772674739 0.6757475 No
row_90 ITGAX ITGAX integrin,	  alpha	  X	  (complement	  component	  3	  receptor	  4	  subunit) 2898 0.752966523 0.6745189 No
row_91 IER3 IER3 immediate	  early	  response	  3 3054 0.718982935 0.6694626 No
row_92 PRC1 PRC1 protein	  regulator	  of	  cytokinesis	  1 3147 0.702128828 0.6676879 No
row_93 ZDHHC2 ZDHHC2 zinc	  finger,	  DHHC-­‐type	  containing	  2 3316 0.668632925 0.66171473 No
row_94 KCNJ8 KCNJ8 potassium	  inwardly-­‐rectifying	  channel,	  subfamily	  J,	  member	  8 3565 0.622722626 0.6512748 No
row_95 PRR11 PRR11 proline	  rich	  11 3576 0.62104547 0.6535079 No
row_96 GZMK GZMK granzyme	  K	  (granzyme	  3;	  tryptase	  II) 3622 0.614801168 0.65384835 No
row_97 NABP1 null null 3696 0.603634 0.65264726 No
row_98 ARHGAP26 ARHGAP26 Rho	  GTPase	  activating	  protein	  26 3752 0.59414047 0.65236294 No
row_99 NOD1 null null 3788 0.589279234 0.65312254 No
row_100 CCR5 CCR5 chemokine	  (C-­‐C	  motif)	  receptor	  5 3858 0.57842803 0.65202236 No
row_101 MAPRE2 MAPRE2 microtubule-­‐associated	  protein,	  RP/EB	  family,	  member	  2 3870 0.577029943 0.6540061 No
row_102 FAM204A null null 3886 0.574480057 0.6557654 No
row_103 ELL2 ELL2 elongation	  factor,	  RNA	  polymerase	  II,	  2 3978 0.556759 0.65339655 No
row_104 DAPK2 DAPK2 death-­‐associated	  protein	  kinase	  2 4080 0.540438652 0.6504222 No
row_105 CD38 CD38 CD38	  molecule 4498 0.478245825 0.6303346 No
row_106 FGL2 FGL2 fibrinogen-­‐like	  2 4605 0.466220081 0.62676334 No
row_107 SERPINB9 SERPINB9 serpin	  peptidase	  inhibitor,	  clade	  B	  (ovalbumin),	  member	  9 4733 0.447111845 0.62198806 No
row_108 RUNX1 RUNX1 runt-­‐related	  transcription	  factor	  1	  (acute	  myeloid	  leukemia	  1;	  aml1	  oncogene) 4775 0.441229612 0.62176865 No
row_109 PDE8A PDE8A phosphodiesterase	  8A 4779 0.440728962 0.62357163 No
row_110 CPEB2 CPEB2 cytoplasmic	  polyadenylation	  element	  binding	  protein	  2 4840 0.432008088 0.62229884 No
row_111 CCNB2 CCNB2 cyclin	  B2 4902 0.424213678 0.62093806 No
row_112 RNF216 null null 4949 0.418337315 0.6203503 No
row_113 KLRK1 KLRK1 killer	  cell	  lectin-­‐like	  receptor	  subfamily	  K,	  member	  1 5195 0.387992203 0.6090248 No
row_114 PRUNE PRUNE prune	  homolog	  (Drosophila) 5385 0.366202533 0.60058594 No
row_115 CYSLTR2 CYSLTR2 cysteinyl	  leukotriene	  receptor	  2 5555 0.350188047 0.5931413 No
row_116 METTL7A METTL7A methyltransferase	  like	  7A 5745 0.330821484 0.58454484 No
row_117 LAMC1 LAMC1 laminin,	  gamma	  1	  (formerly	  LAMB2) 6032 0.300099283 0.5706434 No
8row_118 IL12RB2 IL12RB2 interleukin	  12	  receptor,	  beta	  2 6066 0.29641816 0.57020533 No
row_119 NRP1 NRP1 neuropilin	  1 6243 0.279611409 0.56207347 No
row_120 CHPT1 CHPT1 choline	  phosphotransferase	  1 6252 0.279017806 0.5628898 No
row_121 RPA2 RPA2 replication	  protein	  A2,	  32kDa 6281 0.275597423 0.5626254 No
row_122 NUDT4 NUDT4 nudix	  (nucleoside	  diphosphate	  linked	  moiety	  X)-­‐type	  motif	  4 6342 0.268916696 0.56062627 No
row_123 TM6SF1 TM6SF1 transmembrane	  6	  superfamily	  member	  1 6361 0.266775548 0.5608553 No
row_124 F2RL2 F2RL2 coagulation	  factor	  II	  (thrombin)	  receptor-­‐like	  2 6367 0.266414434 0.56177545 No
row_125 NCAPG NCAPG non-­‐SMC	  condensin	  I	  complex,	  subunit	  G 6414 0.2617791 0.5604904 No
row_126 CASC5 CASC5 cancer	  susceptibility	  candidate	  5 6573 0.245987505 0.5531678 No
row_127 PLOD2 PLOD2 procollagen-­‐lysine,	  2-­‐oxoglutarate	  5-­‐dioxygenase	  2 6580 0.24478434 0.5539383 No
row_128 GBP4 GBP4 guanylate	  binding	  protein	  4 6681 0.235348612 0.5496585 No
row_129 ESM1 ESM1 endothelial	  cell-­‐specific	  molecule	  1 6827 0.220466107 0.54291487 No
row_130 STMN1 STMN1 stathmin	  1/oncoprotein	  18 7111 0.19096157 0.52868724 No
row_131 ATF6 ATF6 activating	  transcription	  factor	  6 7209 0.181822732 0.52432895 No
row_132 CLIC4 CLIC4 chloride	  intracellular	  channel	  4 7692 0.13941212 0.49926916 No
row_133 CXCR6 CXCR6 chemokine	  (C-­‐X-­‐C	  motif)	  receptor	  6 8054 0.106374994 0.48050907 No
row_134 CD44 CD44 CD44	  molecule	  (Indian	  blood	  group) 8103 0.102266327 0.4784071 No
row_135 EEA1 EEA1 early	  endosome	  antigen	  1,	  162kD 8584 0.063421227 0.45311546 No
row_136 VIM VIM vimentin 9105 0.021833856 0.42550746 No
row_137 MYADM MYADM myeloid-­‐associated	  differentiation	  marker 9817 -­‐0.020807154 0.3877185 No T-­‐Naive	  biased
row_138 MKI67 MKI67 antigen	  identified	  by	  monoclonal	  antibody	  Ki-­‐67 9850 -­‐0.023376763 0.38611767 No
row_139 KIAA0101 KIAA0101 KIAA0101 9923 -­‐0.029381931 0.3824124 No
row_140 ITGA1 ITGA1 integrin,	  alpha	  1 10477 -­‐0.07660681 0.3532901 No
row_141 ST3GAL6 ST3GAL6 ST3	  beta-­‐galactoside	  alpha-­‐2,3-­‐sialyltransferase	  6 10483 -­‐0.076973282 0.35336652 No
row_142 CROT CROT carnitine	  O-­‐octanoyltransferase 10549 -­‐0.082258396 0.3502697 No
row_143 NUSAP1 NUSAP1 nucleolar	  and	  spindle	  associated	  protein	  1 10569 -­‐0.083916672 0.34963113 No
row_144 NDNF null null 10795 -­‐0.101919957 0.33809718 No
row_145 AS3MT AS3MT arsenic	  (+3	  oxidation	  state)	  methyltransferase 10916 -­‐0.110689312 0.33219662 No
row_146 USP48 USP48 ubiquitin	  specific	  peptidase	  48 11039 -­‐0.121618956 0.3262382 No
row_147 TTC39B null null 11153 -­‐0.130319729 0.32079798 No
row_148 INSL6 INSL6 insulin-­‐like	  6 11231 -­‐0.136164784 0.3173019 No
row_149 LAIR1 LAIR1 leukocyte-­‐associated	  immunoglobulin-­‐like	  receptor	  1 11995 -­‐0.199535102 0.27753842 No
row_150 APOBEC2 APOBEC2 apolipoprotein	  B	  mRNA	  editing	  enzyme,	  catalytic	  polypeptide-­‐like	  2 12148 -­‐0.213587001 0.27039117 No
row_151 CA5B CA5B carbonic	  anhydrase	  VB,	  mitochondrial 12176 -­‐0.216359437 0.2699162 No
row_152 GPX8 null null 12358 -­‐0.229924336 0.2612966 No
row_153 TTC39C null null 12451 -­‐0.236867934 0.2574498 No
row_154 S100A9 S100A9 S100	  calcium	  binding	  protein	  A9 12649 -­‐0.252709955 0.24807924 No
row_155 PLSCR1 PLSCR1 phospholipid	  scramblase	  1 13247 -­‐0.305294454 0.21763112 No
row_156 LGALSL null null 13438 -­‐0.32125023 0.20893875 No
row_157 GIMAP7 GIMAP7 GTPase,	  IMAP	  family	  member	  7 13941 -­‐0.372332722 0.18385072 No
row_158 KIF11 KIF11 kinesin	  family	  member	  11 14172 -­‐0.395769566 0.17335905 No
row_159 PFKP PFKP phosphofructokinase,	  platelet 14258 -­‐0.406878978 0.17064238 No
row_160 TOP2A TOP2A topoisomerase	  (DNA)	  II	  alpha	  170kDa 14614 -­‐0.448333681 0.15372488 No
row_161 ABCB1 ABCB1 ATP-­‐binding	  cassette,	  sub-­‐family	  B	  (MDR/TAP),	  member	  1 14816 -­‐0.4721964 0.14511868 No
row_162 ENTPD1 ENTPD1 ectonucleoside	  triphosphate	  diphosphohydrolase	  1 15062 -­‐0.5 0.13429202 No
row_163 DDX28 DDX28 DEAD	  (Asp-­‐Glu-­‐Ala-­‐Asp)	  box	  polypeptide	  28 15159 -­‐0.51004833 0.13144873 No
row_164 SPC25 null null 15182 -­‐0.512632906 0.13255963 No
row_165 EMP1 EMP1 epithelial	  membrane	  protein	  1 15494 -­‐0.558685958 0.11847789 No
row_166 PTGER4 PTGER4 prostaglandin	  E	  receptor	  4	  (subtype	  EP4) 15502 -­‐0.559961319 0.120598756 No
row_167 TRPS1 TRPS1 trichorhinophalangeal	  syndrome	  I 15864 -­‐0.615894198 0.10410783 No
row_168 PRKAR2B PRKAR2B protein	  kinase,	  cAMP-­‐dependent,	  regulatory,	  type	  II,	  beta 16668 -­‐0.758772969 0.064703755 No
row_169 GSTM3 GSTM3 glutathione	  S-­‐transferase	  M3	  (brain) 16749 -­‐0.77436173 0.06389007 No
row_170 BCL2A1 BCL2A1 BCL2-­‐related	  protein	  A1 17032 -­‐0.847740293 0.052640747 No
row_171 DENND4A DENND4A DENN/MADD	  domain	  containing	  4A 18063 -­‐1.284453034 0.003483407 No
row_172 EID3 EID3 -­‐ 18196 -­‐1.37605083 0.00257885 No
row_173 SYPL1 SYPL1 synaptophysin-­‐like	  1 18299 -­‐1.472677708 0.003703007 No
row_174 CD48 CD48 CD48	  molecule 18401 -­‐1.591840267 0.005411139 No
row_175 CCNA2 CCNA2 cyclin	  A2 18565 -­‐1.803973913 0.0047607 No












row_0 DUSP10 DUSP10 dual	  specificity	  phosphatase	  10 141 2.939956188 0.011949813 No T-­‐EFF	  biased
row_1 PIP4K2A null null 199 2.746984005 0.027089376 No Normalized	  Enrichment	  Score	  (NES) -­‐2.4599857
row_2 XCL1 XCL1 chemokine	  (C	  motif)	  ligand	  1 329 2.424889326 0.036270257 No Nominal	  p-­‐value 0
row_3 SH3BP5 SH3BP5 SH3-­‐domain	  binding	  protein	  5	  (BTK-­‐associated) 434 2.161664009 0.04503923 No FDR	  q-­‐value 0
row_4 HSPB11 null null 794 1.710548043 0.03726619 No FWER	  p-­‐Value 0
row_5 TOX TOX -­‐ 1049 1.482677102 0.03356861 No
row_6 MRPS5 MRPS5 mitochondrial	  ribosomal	  protein	  S5 1126 1.428400517 0.038976066 No
row_7 SLAMF6 SLAMF6 SLAM	  family	  member	  6 1145 1.419834614 0.04741066 No
row_8 IFI27L2 null null 1403 1.269733906 0.042145036 No
row_9 LZTFL1 LZTFL1 leucine	  zipper	  transcription	  factor-­‐like	  1 1557 1.191928625 0.041894328 No
row_10 LY6E LY6E lymphocyte	  antigen	  6	  complex,	  locus	  E 1603 1.174182415 0.04726847 No
row_11 EMB EMB embigin	  homolog	  (mouse) 1737 1.11072886 0.047544036 No
row_12 ST8SIA1 ST8SIA1 ST8	  alpha-­‐N-­‐acetyl-­‐neuraminide	  alpha-­‐2,8-­‐sialyltransferase	  1 1791 1.085347176 0.05190522 No
row_13 STAMBPL1 STAMBPL1 STAM	  binding	  protein-­‐like	  1 1935 1.02846241 0.051104933 No
row_14 MED4 MED4 mediator	  of	  RNA	  polymerase	  II	  transcription,	  subunit	  4	  homolog	  (S.	  cerevisiae) 2034 0.994327545 0.05247146 No
row_15 RTP4 RTP4 receptor	  transporter	  protein	  4 2082 0.977881908 0.056440815 No
row_16 PHPT1 PHPT1 phosphohistidine	  phosphatase	  1 2204 0.936563373 0.05620237 No
row_17 EGR2 EGR2 early	  growth	  response	  2	  (Krox-­‐20	  homolog,	  Drosophila) 2325 0.900809228 0.055780597 No
row_18 SPRED2 SPRED2 sprouty-­‐related,	  EVH1	  domain	  containing	  2 2460 0.864051044 0.05437132 No
row_19 RPLP1 RPLP1 ribosomal	  protein,	  large,	  P1 2933 0.746564031 0.034213834 No
row_20 ATP1B1 ATP1B1 ATPase,	  Na+/K+	  transporting,	  beta	  1	  polypeptide 3246 0.683011651 0.022142995 No
row_21 NAT1 NAT1 N-­‐acetyltransferase	  1	  (arylamine	  N-­‐acetyltransferase) 3671 0.606945157 0.003614093 No
row_22 HINT3 HINT3 histidine	  triad	  nucleotide	  binding	  protein	  3 4043 0.546061218 -­‐0.012499581 No
row_23 ITGAE ITGAE integrin,	  alpha	  E	  (antigen	  CD103,	  human	  mucosal	  lymphocyte	  antigen	  1;	  alpha	  polypeptide) 4278 0.5118379 -­‐0.021555495 No
row_24 USP28 USP28 ubiquitin	  specific	  peptidase	  28 4424 0.48942703 -­‐0.026027618 No
row_25 GID4 null null 4838 0.432452857 -­‐0.045125857 No
row_26 HMP19 HMP19 -­‐ 4885 0.425784498 -­‐0.04475523 No
row_27 JUN JUN jun	  oncogene 5091 0.399972111 -­‐0.053009197 No
row_28 ACSL3 ACSL3 acyl-­‐CoA	  synthetase	  long-­‐chain	  family	  member	  3 5165 0.391422004 -­‐0.054301426 No
row_29 SLFN5 SLFN5 schlafen	  family	  member	  5 5772 0.32738024 -­‐0.08435627 No
row_30 BCL9 BCL9 B-­‐cell	  CLL/lymphoma	  9 6430 0.260354906 -­‐0.11756607 No
row_31 CCR9 CCR9 chemokine	  (C-­‐C	  motif)	  receptor	  9 6700 0.233178288 -­‐0.1303261 No
row_32 TTC27 TTC27 tetratricopeptide	  repeat	  domain	  27 6854 0.218153343 -­‐0.13701795 No
row_33 CD3D CD3D CD3d	  molecule,	  delta	  (CD3-­‐TCR	  complex) 6890 0.215069339 -­‐0.13745627 No
row_34 LPHN2 LPHN2 latrophilin	  2 6942 0.210390016 -­‐0.13877623 No
row_35 SEPP1 SEPP1 selenoprotein	  P,	  plasma,	  1 7007 0.202965602 -­‐0.1408365 No
row_36 HRSP12 HRSP12 heat-­‐responsive	  protein	  12 7324 0.171926096 -­‐0.15650065 No
row_37 PPIC PPIC peptidylprolyl	  isomerase	  C	  (cyclophilin	  C) 7382 0.1669918 -­‐0.15842669 No
row_38 EPHX1 EPHX1 epoxide	  hydrolase	  1,	  microsomal	  (xenobiotic) 7497 0.156613216 -­‐0.163452 No
row_39 IFT80 IFT80 intraflagellar	  transport	  80	  homolog	  (Chlamydomonas) 7613 0.146471366 -­‐0.16859758 No
row_40 PRDX6 PRDX6 peroxiredoxin	  6 7705 0.138377637 -­‐0.17252062 No
row_41 RPS26 RPS26 ribosomal	  protein	  S26 7821 0.12824057 -­‐0.17778678 No
row_42 TLR1 TLR1 toll-­‐like	  receptor	  1 8020 0.109741025 -­‐0.18758833 No
row_43 TMLHE TMLHE trimethyllysine	  hydroxylase,	  epsilon 8072 0.104750194 -­‐0.18960707 No
row_44 TRIM13 TRIM13 tripartite	  motif-­‐containing	  13 8261 0.088052206 -­‐0.19902039 No
row_45 NEDD4L NEDD4L neural	  precursor	  cell	  expressed,	  developmentally	  down-­‐regulated	  4-­‐like 8274 0.0869992 -­‐0.19908294 No
row_46 DAPL1 DAPL1 death	  associated	  protein-­‐like	  1 8730 0.05147025 -­‐0.22293432 No
row_47 QSER1 QSER1 glutamine	  and	  serine	  rich	  1 9237 0.011975013 -­‐0.24975856 No
row_48 GRIA3 GRIA3 glutamate	  receptor,	  ionotrophic,	  AMPA	  3 10043 -­‐0.039689511 -­‐0.29229698 No T-­‐Naive	  biased
row_49 DKC1 DKC1 dyskeratosis	  congenita	  1,	  dyskerin 10139 -­‐0.049450032 -­‐0.2970209 No
row_50 RRAS2 RRAS2 related	  RAS	  viral	  (r-­‐ras)	  oncogene	  homolog	  2 10748 -­‐0.098168731 -­‐0.32869825 No
row_51 LYPD6B null null 10756 -­‐0.098722182 -­‐0.32841742 No
row_52 F2RL1 F2RL1 coagulation	  factor	  II	  (thrombin)	  receptor-­‐like	  1 11236 -­‐0.136392936 -­‐0.35298312 No
row_53 DPP4 DPP4 dipeptidyl-­‐peptidase	  4	  (CD26,	  adenosine	  deaminase	  complexing	  protein	  2) 11283 -­‐0.140664518 -­‐0.35449845 No
row_54 RAPGEF4 RAPGEF4 Rap	  guanine	  nucleotide	  exchange	  factor	  (GEF)	  4 11391 -­‐0.149277762 -­‐0.3592001 No
row_55 TFRC TFRC transferrin	  receptor	  (p90,	  CD71) 11483 -­‐0.15601249 -­‐0.3630065 No
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row_56 KIAA1033 KIAA1033 KIAA1033 11781 -­‐0.183877766 -­‐0.3775814 No
row_57 ICOS ICOS inducible	  T-­‐cell	  co-­‐stimulator 11945 -­‐0.196053505 -­‐0.38495108 No
row_58 RRP15 null null 12080 -­‐0.207625285 -­‐0.39070237 No
row_59 INSR INSR insulin	  receptor 12743 -­‐0.260480523 -­‐0.42417717 No
row_60 CD2AP CD2AP CD2-­‐associated	  protein 12789 -­‐0.264684618 -­‐0.424819 No
row_61 TSPAN13 TSPAN13 tetraspanin	  13 13458 -­‐0.323553056 -­‐0.45819563 No
row_62 MGST2 MGST2 microsomal	  glutathione	  S-­‐transferase	  2 13478 -­‐0.325819671 -­‐0.45705065 No
row_63 XKRX XKRX XK,	  Kell	  blood	  group	  complex	  subunit-­‐related,	  X-­‐linked 13496 -­‐0.328198284 -­‐0.45578364 No
row_64 ZNF761 ZNF761 zinc	  finger	  protein	  761 13578 -­‐0.335966825 -­‐0.45786804 No
row_65 RPS29 RPS29 ribosomal	  protein	  S29 13767 -­‐0.35352698 -­‐0.46552533 No
row_66 CHURC1 CHURC1 churchill	  domain	  containing	  1 13799 -­‐0.356838018 -­‐0.46481323 No
row_67 RPL8 RPL8 ribosomal	  protein	  L8 13990 -­‐0.376885176 -­‐0.47242236 No
row_68 LCLAT1 null null 14502 -­‐0.434282362 -­‐0.49671906 No
row_69 CNGA1 CNGA1 cyclic	  nucleotide	  gated	  channel	  alpha	  1 14777 -­‐0.467894018 -­‐0.5081924 No
row_70 RPSA RPSA ribosomal	  protein	  SA 14858 -­‐0.476895005 -­‐0.5092914 No
row_71 WDR12 WDR12 WD	  repeat	  domain	  12 15015 -­‐0.496033192 -­‐0.5143047 No
row_72 KLHDC1 KLHDC1 kelch	  domain	  containing	  1 15155 -­‐0.509133816 -­‐0.5183275 No
row_73 ZBTB10 ZBTB10 zinc	  finger	  and	  BTB	  domain	  containing	  10 15248 -­‐0.523607731 -­‐0.51975554 No
row_74 TTC3 TTC3 tetratricopeptide	  repeat	  domain	  3 15281 -­‐0.528237998 -­‐0.5179629 No
row_75 PCGF5 PCGF5 polycomb	  group	  ring	  finger	  5 15374 -­‐0.540068984 -­‐0.5192821 No
row_76 MYC MYC v-­‐myc	  myelocytomatosis	  viral	  oncogene	  homolog	  (avian) 15574 -­‐0.571345031 -­‐0.52608347 No
row_77 RPL14 RPL14 ribosomal	  protein	  L14 15877 -­‐0.618567109 -­‐0.5380489 No
row_78 TRAT1 TRAT1 T	  cell	  receptor	  associated	  transmembrane	  adaptor	  1 15885 -­‐0.619778156 -­‐0.5343215 No
row_79 RPLP0 RPLP0 ribosomal	  protein,	  large,	  P0 15971 -­‐0.63402319 -­‐0.53464705 No
row_80 CCDC91 CCDC91 coiled-­‐coil	  domain	  containing	  91 16303 -­‐0.687809348 -­‐0.54769635 No
row_81 MRPL23 MRPL23 mitochondrial	  ribosomal	  protein	  L23 16385 -­‐0.704515219 -­‐0.54734296 No
row_82 KBTBD11 KBTBD11 kelch	  repeat	  and	  BTB	  (POZ)	  domain	  containing	  11 16543 -­‐0.733644545 -­‐0.5508377 No
row_83 RPS2 RPS2 ribosomal	  protein	  S2 16655 -­‐0.757363677 -­‐0.5517298 No
row_84 RPS19 RPS19 ribosomal	  protein	  S19 16716 -­‐0.768323898 -­‐0.54983777 No
row_85 RPL10A RPL10A ribosomal	  protein	  L10a 17070 -­‐0.856434166 -­‐0.56294143 No
row_86 CYB5A CYB5A cytochrome	  b5	  type	  A	  (microsomal) 17166 -­‐0.881539941 -­‐0.56216145 No
row_87 BTF3L4 BTF3L4 basic	  transcription	  factor	  3-­‐like	  4 17188 -­‐0.886925817 -­‐0.5574113 No
row_88 IMPDH2 IMPDH2 IMP	  (inosine	  monophosphate)	  dehydrogenase	  2 17415 -­‐0.955320895 -­‐0.56310844 Yes
row_89 CMSS1 null null 17453 -­‐0.969784021 -­‐0.5586609 Yes
row_90 P2RY10 P2RY10 purinergic	  receptor	  P2Y,	  G-­‐protein	  coupled,	  10 17467 -­‐0.974344432 -­‐0.5529072 Yes
row_91 LTV1 LTV1 LTV1	  homolog	  (S.	  cerevisiae) 17636 -­‐1.036688805 -­‐0.5549823 Yes
row_92 TNFSF8 TNFSF8 tumor	  necrosis	  factor	  (ligand)	  superfamily,	  member	  8 17663 -­‐1.047024012 -­‐0.5494391 Yes
row_93 ST6GAL1 ST6GAL1 ST6	  beta-­‐galactosamide	  alpha-­‐2,6-­‐sialyltranferase	  1 17827 -­‐1.123234868 -­‐0.55067587 Yes
row_94 CD69 CD69 CD69	  molecule 17857 -­‐1.142017961 -­‐0.5446638 Yes
row_95 LSM7 LSM7 LSM7	  homolog,	  U6	  small	  nuclear	  RNA	  associated	  (S.	  cerevisiae) 17871 -­‐1.145340919 -­‐0.537779 Yes
row_96 RAB3IP RAB3IP RAB3A	  interacting	  protein	  (rabin3) 17878 -­‐1.147305012 -­‐0.53050905 Yes
row_97 HOOK1 HOOK1 hook	  homolog	  1	  (Drosophila) 17979 -­‐1.21851027 -­‐0.527766 Yes
row_98 SATB1 SATB1 special	  AT-­‐rich	  sequence	  binding	  protein	  1	  (binds	  to	  nuclear	  matrix/scaffold-­‐associating	  DNA's) 17993 -­‐1.225864649 -­‐0.52034855 Yes
row_99 FBL FBL fibrillarin 18055 -­‐1.275766611 -­‐0.51515317 Yes
row_100 SESN3 SESN3 sestrin	  3 18061 -­‐1.280887604 -­‐0.5069465 Yes
row_101 PDE3B PDE3B phosphodiesterase	  3B,	  cGMP-­‐inhibited 18103 -­‐1.315524936 -­‐0.50042474 Yes
row_102 PELI1 PELI1 pellino	  homolog	  1	  (Drosophila) 18124 -­‐1.324875116 -­‐0.4927246 Yes
row_103 SSBP2 SSBP2 single-­‐stranded	  DNA	  binding	  protein	  2 18126 -­‐1.326386809 -­‐0.48400426 Yes
row_104 RPL13 RPL13 ribosomal	  protein	  L13 18189 -­‐1.370167017 -­‐0.47823763 Yes
row_105 APEX1 APEX1 APEX	  nuclease	  (multifunctional	  DNA	  repair	  enzyme)	  1 18231 -­‐1.406233907 -­‐0.4711159 Yes
row_106 INPP4B INPP4B inositol	  polyphosphate-­‐4-­‐phosphatase,	  type	  II,	  105kDa 18255 -­‐1.430721879 -­‐0.46287513 Yes
row_107 RPL29 RPL29 ribosomal	  protein	  L29 18282 -­‐1.452724934 -­‐0.45464832 Yes
row_108 RPL18 RPL18 ribosomal	  protein	  L18 18347 -­‐1.518245578 -­‐0.44800857 Yes
row_109 BZW2 BZW2 basic	  leucine	  zipper	  and	  W2	  domains	  2 18379 -­‐1.561169744 -­‐0.43933028 Yes
row_110 CD27 null null 18403 -­‐1.594195485 -­‐0.4300082 Yes
row_111 GPATCH4 null null 18411 -­‐1.60322082 -­‐0.41977572 Yes
row_112 GPR183 null null 18412 -­‐1.608658433 -­‐0.4091351 Yes
row_113 EEF1B2 EEF1B2 eukaryotic	  translation	  elongation	  factor	  1	  beta	  2 18428 -­‐1.626211882 -­‐0.3991759 Yes
row_114 RPL28 RPL28 ribosomal	  protein	  L28 18463 -­‐1.667272091 -­‐0.3899553 Yes
row_115 TRIB2 TRIB2 tribbles	  homolog	  2	  (Drosophila) 18496 -­‐1.701058149 -­‐0.38040492 Yes
row_116 PDK1 PDK1 pyruvate	  dehydrogenase	  kinase,	  isozyme	  1 18502 -­‐1.709740758 -­‐0.36936152 Yes
row_117 DGKA DGKA diacylglycerol	  kinase,	  alpha	  80kDa 18512 -­‐1.720613718 -­‐0.35845888 Yes
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row_118 TCP11L2 TCP11L2 t-­‐complex	  11	  (mouse)	  like	  2 18552 -­‐1.774849534 -­‐0.34879252 Yes
row_119 RPS9 RPS9 ribosomal	  protein	  S9 18631 -­‐1.944758415 -­‐0.3400759 Yes
row_120 RPL15 RPL15 ribosomal	  protein	  L15 18634 -­‐1.947595 -­‐0.3272997 Yes
row_121 MYB MYB v-­‐myb	  myeloblastosis	  viral	  oncogene	  homolog	  (avian) 18678 -­‐2.026391506 -­‐0.3161822 Yes
row_122 ITGA6 ITGA6 integrin,	  alpha	  6 18768 -­‐2.315096617 -­‐0.3056008 Yes
row_123 SELL SELL selectin	  L	  (lymphocyte	  adhesion	  molecule	  1) 18773 -­‐2.32630682 -­‐0.2904259 Yes
row_124 IL7R IL7R interleukin	  7	  receptor 18808 -­‐2.507570744 -­‐0.27564707 Yes
row_125 ZEB1 null null 18839 -­‐2.68319726 -­‐0.2594939 Yes
row_126 SH3PXD2A SH3PXD2A SH3	  and	  PX	  domains	  2A 18846 -­‐2.73724103 -­‐0.24170715 Yes
row_127 TCF7 TCF7 transcription	  factor	  7	  (T-­‐cell	  specific,	  HMG-­‐box) 18862 -­‐2.879874945 -­‐0.22345547 Yes
row_128 LTB LTB lymphotoxin	  beta	  (TNF	  superfamily,	  member	  3) 18866 -­‐2.933085918 -­‐0.2042138 Yes
row_129 IL6ST IL6ST interleukin	  6	  signal	  transducer	  (gp130,	  oncostatin	  M	  receptor) 18893 -­‐3.206775904 -­‐0.18438466 Yes
row_130 IFNGR2 IFNGR2 interferon	  gamma	  receptor	  2	  (interferon	  gamma	  transducer	  1) 18901 -­‐3.34031558 -­‐0.162662 Yes
row_131 PECAM1 PECAM1 platelet/endothelial	  cell	  adhesion	  molecule	  (CD31	  antigen) 18903 -­‐3.406530619 -­‐0.14018235 Yes
row_132 CCR7 CCR7 chemokine	  (C-­‐C	  motif)	  receptor	  7 18906 -­‐3.42228055 -­‐0.117651686 Yes
row_133 DPH5 DPH5 DPH5	  homolog	  (S.	  cerevisiae) 18907 -­‐3.440943003 -­‐0.094891235 Yes
row_134 RGS10 RGS10 regulator	  of	  G-­‐protein	  signalling	  10 18910 -­‐3.448899031 -­‐0.0721845 Yes
row_135 RPS5 RPS5 ribosomal	  protein	  S5 18913 -­‐3.483943701 -­‐0.049245965 Yes
row_136 ACTN1 ACTN1 actinin,	  alpha	  1 18917 -­‐3.560284615 -­‐0.025855627 Yes













row_0 ITGB1 ITGB1 integrin,	  beta	  1	  (fibronectin	  receptor,	  beta	  polypeptide,	  antigen	  CD29	  includes	  MDF2,	  MSK12) 3 4.403458118 0.033498626 Yes T-­‐MEM	  biased
row_1 TBX21 TBX21 T-­‐box	  21 9 3.787709236 0.06218451 Yes Normalized	  Enrichment	  Score	  (NES) 2.735306
row_2 IER3 IER3 immediate	  early	  response	  3 27 3.474953413 0.087842345 Yes Nominal	  p-­‐value 0
row_3 ANXA2 ANXA2 annexin	  A2 29 3.467990398 0.114296935 Yes FDR	  q-­‐value 0
row_4 IL18R1 IL18R1 interleukin	  18	  receptor	  1 30 3.436789513 0.14056617 Yes FWER	  p-­‐Value 0
row_5 PRDM1 PRDM1 PR	  domain	  containing	  1,	  with	  ZNF	  domain 32 3.428418159 0.16671829 Yes
row_6 TNF TNF tumor	  necrosis	  factor	  (TNF	  superfamily,	  member	  2) 39 3.323193789 0.1918005 Yes
row_7 GZMA GZMA granzyme	  A	  (granzyme	  1,	  cytotoxic	  T-­‐lymphocyte-­‐associated	  serine	  esterase	  3) 63 3.111444473 0.2143611 Yes
row_8 BHLHE40 null null 83 2.946973085 0.23587705 Yes
row_9 CXCR3 CXCR3 chemokine	  (C-­‐X-­‐C	  motif)	  receptor	  3 84 2.945517063 0.25839123 Yes
row_10 MYO1F MYO1F myosin	  IF 96 2.830258846 0.27944005 Yes
row_11 GZMK GZMK granzyme	  K	  (granzyme	  3;	  tryptase	  II) 101 2.814285755 0.30073866 Yes
row_12 CCL5 CCL5 chemokine	  (C-­‐C	  motif)	  ligand	  5 103 2.810801268 0.32217 Yes
row_13 SLAMF7 SLAMF7 SLAM	  family	  member	  7 112 2.729997635 0.34261185 Yes
row_14 IFNG IFNG interferon,	  gamma 168 2.514009953 0.35890597 Yes
row_15 ZEB2 null null 203 2.384581566 0.37532642 Yes
row_16 IL18RAP IL18RAP interleukin	  18	  receptor	  accessory	  protein 205 2.380190134 0.39346638 Yes
row_17 CAMK2N1 CAMK2N1 calcium/calmodulin-­‐dependent	  protein	  kinase	  II	  inhibitor	  1 206 2.379069328 0.41165087 Yes
row_18 PTPRJ PTPRJ protein	  tyrosine	  phosphatase,	  receptor	  type,	  J 210 2.366587877 0.4295806 Yes
row_19 S1PR5 null null 213 2.358679295 0.44750303 Yes
row_20 XCL1 XCL1 chemokine	  (C	  motif)	  ligand	  1 246 2.268402576 0.46314168 Yes
row_21 LGALS1 LGALS1 lectin,	  galactoside-­‐binding,	  soluble,	  1	  (galectin	  1) 262 2.228570938 0.479379 Yes
row_22 FCHO2 FCHO2 FCH	  domain	  only	  2 299 2.135591984 0.49379003 Yes
row_23 RGS1 RGS1 regulator	  of	  G-­‐protein	  signalling	  1 305 2.109815836 0.5096509 Yes
row_24 CCL4 CCL4 chemokine	  (C-­‐C	  motif)	  ligand	  4 368 1.997584224 0.5216258 Yes
row_25 CD44 CD44 CD44	  molecule	  (Indian	  blood	  group) 508 1.743003964 0.52756435 Yes
row_26 HOPX null null 511 1.739763975 0.54075605 Yes
row_27 IL2RB IL2RB interleukin	  2	  receptor,	  beta 605 1.639035821 0.54834354 Yes
row_28 CCR5 CCR5 chemokine	  (C-­‐C	  motif)	  receptor	  5 627 1.613669157 0.5595621 Yes
row_29 S100A4 S100A4 S100	  calcium	  binding	  protein	  A4 637 1.605283499 0.57135403 Yes
row_30 CHSY1 CHSY1 carbohydrate	  (chondroitin)	  synthase	  1 656 1.586069226 0.582521 Yes
row_31 ITGA4 ITGA4 integrin,	  alpha	  4	  (antigen	  CD49D,	  alpha	  4	  subunit	  of	  VLA-­‐4	  receptor) 783 1.489005804 0.5872087 Yes
row_32 AHNAK AHNAK AHNAK	  nucleoprotein	  (desmoyokin) 925 1.377583385 0.59024787 Yes
row_33 TYROBP TYROBP TYRO	  protein	  tyrosine	  kinase	  binding	  protein 1012 1.307673335 0.59567446 Yes
row_34 FASLG FASLG Fas	  ligand	  (TNF	  superfamily,	  member	  6) 1108 1.245491982 0.60014766 Yes
row_35 PTPN3 PTPN3 protein	  tyrosine	  phosphatase,	  non-­‐receptor	  type	  3 1121 1.241511583 0.6089997 Yes
row_36 ATP2B1 ATP2B1 ATPase,	  Ca++	  transporting,	  plasma	  membrane	  1 1266 1.171560645 0.61030483 Yes
row_37 CTSD CTSD cathepsin	  D	  (lysosomal	  aspartyl	  peptidase) 1342 1.137916207 0.61501825 Yes
row_38 ID2 ID2 inhibitor	  of	  DNA	  binding	  2,	  dominant	  negative	  helix-­‐loop-­‐helix	  protein 1353 1.132620811 0.6231442 Yes
row_39 CASP4 CASP4 caspase	  4,	  apoptosis-­‐related	  cysteine	  peptidase 1364 1.127617121 0.63123196 Yes
row_40 ANXA1 ANXA1 annexin	  A1 1367 1.12607944 0.63973296 Yes
row_41 GZMB GZMB granzyme	  B	  (granzyme	  2,	  cytotoxic	  T-­‐lymphocyte-­‐associated	  serine	  esterase	  1) 1387 1.118411899 0.6472722 Yes
row_42 PLEK PLEK pleckstrin 1396 1.115830541 0.65537614 Yes
row_43 KLRG1 KLRG1 killer	  cell	  lectin-­‐like	  receptor	  subfamily	  G,	  member	  1 1485 1.075441837 0.6589214 Yes
row_44 SAMD3 SAMD3 sterile	  alpha	  motif	  domain	  containing	  3 1649 1.020359516 0.65806144 Yes
row_45 P2RY13 P2RY13 purinergic	  receptor	  P2Y,	  G-­‐protein	  coupled,	  13 1768 0.977391183 0.65926355 Yes
row_46 HMOX1 HMOX1 heme	  oxygenase	  (decycling)	  1 1836 0.954161108 0.6629974 Yes
row_47 VCAM1 VCAM1 vascular	  cell	  adhesion	  molecule	  1 2118 0.876853645 0.654772 No
row_48 CDC42EP3 CDC42EP3 CDC42	  effector	  protein	  (Rho	  GTPase	  binding)	  3 2405 0.811948538 0.64578474 No
row_49 RORA RORA RAR-­‐related	  orphan	  receptor	  A 2483 0.79405731 0.6477636 No
row_50 SLC25A24 SLC25A24 solute	  carrier	  family	  25	  (mitochondrial	  carrier;	  phosphate	  carrier),	  member	  24 2523 0.785699964 0.65169734 No
row_51 CAPN2 CAPN2 calpain	  2,	  (m/II)	  large	  subunit 2575 0.775719941 0.6549173 No
row_52 DSTN DSTN destrin	  (actin	  depolymerizing	  factor) 2742 0.739924014 0.6517544 No
row_53 CD38 CD38 CD38	  molecule 2824 0.724371314 0.65298814 No
row_54 S100A6 S100A6 S100	  calcium	  binding	  protein	  A6 2842 0.721523046 0.6576 No
row_55 MITF MITF microphthalmia-­‐associated	  transcription	  factor 3146 0.671954572 0.64663965 No
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row_56 UBD UBD ubiquitin	  D 3333 0.644224048 0.6416828 No
row_57 SLC9A7 SLC9A7 solute	  carrier	  family	  9	  (sodium/hydrogen	  exchanger),	  member	  7 3405 0.633073628 0.64274997 No
row_58 IGF1 IGF1 insulin-­‐like	  growth	  factor	  1	  (somatomedin	  C) 3628 0.601582348 0.6355547 No
row_59 CTSB CTSB cathepsin	  B 3760 0.581756353 0.63304216 No
row_60 KLRC1 KLRC1 killer	  cell	  lectin-­‐like	  receptor	  subfamily	  C,	  member	  1 4033 0.549523294 0.62279284 No
row_61 SYTL2 SYTL2 synaptotagmin-­‐like	  2 4107 0.540566444 0.62304664 No
row_62 ARHGAP26 ARHGAP26 Rho	  GTPase	  activating	  protein	  26 4308 0.515345871 0.61636096 No
row_63 PILRA PILRA paired	  immunoglobin-­‐like	  type	  2	  receptor	  alpha 4785 0.458973765 0.5945823 No
row_64 GOLIM4 null null 4971 0.43950215 0.5881138 No
row_65 GNPTAB GNPTAB N-­‐acetylglucosamine-­‐1-­‐phosphate	  transferase,	  alpha	  and	  beta	  subunits 5275 0.404915243 0.5751123 No
row_66 ZDHHC2 ZDHHC2 zinc	  finger,	  DHHC-­‐type	  containing	  2 5375 0.395494431 0.57287604 No
row_67 ITGA1 ITGA1 integrin,	  alpha	  1 5481 0.38406226 0.57023364 No
row_68 CASP1 CASP1 caspase	  1,	  apoptosis-­‐related	  cysteine	  peptidase	  (interleukin	  1,	  beta,	  convertase) 5553 0.378048152 0.5693515 No
row_69 DOCK5 DOCK5 dedicator	  of	  cytokinesis	  5 5680 0.365191877 0.56544924 No
row_70 C1QB C1QB complement	  component	  1,	  q	  subcomponent,	  B	  chain 5736 0.359394342 0.5652745 No
row_71 CX3CR1 CX3CR1 chemokine	  (C-­‐X3-­‐C	  motif)	  receptor	  1 5825 0.350362927 0.5632776 No
row_72 SIRPA SIRPA signal-­‐regulatory	  protein	  alpha 5967 0.337242603 0.5583649 No
row_73 CEP290 CEP290 centrosomal	  protein	  290kDa 6252 0.308049321 0.54563236 No
row_74 ABCB1 ABCB1 ATP-­‐binding	  cassette,	  sub-­‐family	  B	  (MDR/TAP),	  member	  1 6346 0.298542351 0.54297376 No
row_75 KCNJ8 KCNJ8 potassium	  inwardly-­‐rectifying	  channel,	  subfamily	  J,	  member	  8 6525 0.280597478 0.53566253 No
row_76 SIGLEC8 SIGLEC8 sialic	  acid	  binding	  Ig-­‐like	  lectin	  8 6635 0.270513564 0.53193974 No
row_77 ENTPD1 ENTPD1 ectonucleoside	  triphosphate	  diphosphohydrolase	  1 6960 0.239131674 0.5165555 No
row_78 CHD7 CHD7 chromodomain	  helicase	  DNA	  binding	  protein	  7 7633 0.179831967 0.4822309 No
row_79 MRC1 MRC1 mannose	  receptor,	  C	  type	  1 7750 0.169954807 0.4773676 No
row_80 NOD1 null null 8023 0.147540331 0.4640457 No
row_81 SLC20A1 SLC20A1 solute	  carrier	  family	  20	  (phosphate	  transporter),	  member	  1 8085 0.141955048 0.46189022 No
row_82 CLEC12A CLEC12A C-­‐type	  lectin	  domain	  family	  12,	  member	  A 8121 0.139091328 0.46109402 No
row_83 KLRK1 KLRK1 killer	  cell	  lectin-­‐like	  receptor	  subfamily	  K,	  member	  1 8756 0.083828688 0.42805436 No
row_84 MARCO MARCO macrophage	  receptor	  with	  collagenous	  structure 8799 0.079154007 0.4264282 No
row_85 BCL2A1 BCL2A1 BCL2-­‐related	  protein	  A1 8955 0.066597454 0.41870305 No
row_86 C1QC C1QC complement	  component	  1,	  q	  subcomponent,	  C	  chain 9054 0.057710547 0.41393805 No
row_87 FGL2 FGL2 fibrinogen-­‐like	  2 9285 0.039783955 0.4020237 No
row_88 CYSLTR2 CYSLTR2 cysteinyl	  leukotriene	  receptor	  2 9309 0.03815094 0.40109345 No
row_89 CD68 CD68 CD68	  molecule 9565 0.014540591 0.38765806 No T-­‐Naive	  biased
row_90 CD5L CD5L CD5	  molecule-­‐like 9589 0.012351896 0.38653064 No
row_91 SPIC SPIC Spi-­‐C	  transcription	  factor	  (Spi-­‐1/PU.1	  related) 9974 -­‐0.013060934 0.36623096 No
row_92 KCNJ16 KCNJ16 potassium	  inwardly-­‐rectifying	  channel,	  subfamily	  J,	  member	  16 10081 -­‐0.021453133 0.36076385 No
row_93 MARCKS MARCKS myristoylated	  alanine-­‐rich	  protein	  kinase	  C	  substrate 10100 -­‐0.023070196 0.35998395 No
row_94 TF TF transferrin 10110 -­‐0.023738414 0.3596873 No
row_95 C1QA C1QA complement	  component	  1,	  q	  subcomponent,	  A	  chain 10307 -­‐0.038720008 0.34957102 No
row_96 DMRTA1 DMRTA1 DMRT-­‐like	  family	  A1 10492 -­‐0.053806484 0.34020752 No
row_97 CD302 CD302 CD302	  molecule 10626 -­‐0.066097707 0.3336473 No
row_98 PLBD1 null null 10770 -­‐0.080001555 0.3266621 No
row_99 TM6SF1 TM6SF1 transmembrane	  6	  superfamily	  member	  1 11164 -­‐0.115543537 0.30666766 No
row_100 CXCL3 CXCL3 chemokine	  (C-­‐X-­‐C	  motif)	  ligand	  3 11234 -­‐0.12114767 0.30392814 No
row_101 MYADM MYADM myeloid-­‐associated	  differentiation	  marker 11320 -­‐0.129930556 0.30040574 No
row_102 EEA1 EEA1 early	  endosome	  antigen	  1,	  162kD 11628 -­‐0.158786342 0.28531048 No
row_103 LGMN LGMN legumain 11900 -­‐0.183479294 0.2723164 No
row_104 SERPINB6 SERPINB6 serpin	  peptidase	  inhibitor,	  clade	  B	  (ovalbumin),	  member	  6 12789 -­‐0.268000066 0.22719103 No
row_105 ADAMDEC1 ADAMDEC1 ADAM-­‐like,	  decysin	  1 13104 -­‐0.301389694 0.21281388 No
row_106 ATP6V0D2 ATP6V0D2 ATPase,	  H+	  transporting,	  lysosomal	  38kDa,	  V0	  subunit	  d2 13305 -­‐0.322526693 0.2046544 No
row_107 APOE APOE apolipoprotein	  E 13579 -­‐0.353963107 0.19285716 No
row_108 RAB23 RAB23 RAB23,	  member	  RAS	  oncogene	  family 14232 -­‐0.426638871 0.16148156 No
row_109 CCR3 CCR3 chemokine	  (C-­‐C	  motif)	  receptor	  3 14513 -­‐0.457534194 0.1501041 No
row_110 SLC40A1 SLC40A1 solute	  carrier	  family	  40	  (iron-­‐regulated	  transporter),	  member	  1 15204 -­‐0.549991131 0.11765265 No
row_111 IL18 IL18 interleukin	  18	  (interferon-­‐gamma-­‐inducing	  factor) 15396 -­‐0.576450884 0.11191215 No
row_112 EMR1 EMR1 egf-­‐like	  module	  containing,	  mucin-­‐like,	  hormone	  receptor-­‐like	  1 15417 -­‐0.58118856 0.11529201 No
row_113 TTC39B null null 15473 -­‐0.589318216 0.11687469 No
row_114 TRPS1 TRPS1 trichorhinophalangeal	  syndrome	  I 15933 -­‐0.662678242 0.09755613 No
row_115 MPEG1 MPEG1 -­‐ 16069 -­‐0.689519227 0.0956548 No
row_116 MERTK MERTK c-­‐mer	  proto-­‐oncogene	  tyrosine	  kinase 16455 -­‐0.769379318 0.08108297 No
row_117 CD163 CD163 CD163	  molecule 16576 -­‐0.799468338 0.08081889 No
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row_118 CSF1R CSF1R colony	  stimulating	  factor	  1	  receptor,	  formerly	  McDonough	  feline	  sarcoma	  viral	  (v-­‐fms)	  oncogene	  homolog17321 -­‐1.016953349 0.049068 No
row_119 DENND4A DENND4A DENN/MADD	  domain	  containing	  4A 17562 -­‐1.106143713 0.044773173 No
row_120 HPGD HPGD hydroxyprostaglandin	  dehydrogenase	  15-­‐(NAD) 17591 -­‐1.119443536 0.05184222 No













row_0 TRAT1 TRAT1 T	  cell	  receptor	  associated	  transmembrane	  adaptor	  1 252 2.253664494 0.015806396 No T-­‐MEM	  biased
row_1 IFT52 IFT52 intraflagellar	  transport	  52	  homolog	  (Chlamydomonas) 448 1.839338064 0.029272709 No Normalized	  Enrichment	  Score	  (NES) -­‐1.7465168
row_2 MAP1LC3B MAP1LC3B microtubule-­‐associated	  protein	  1	  light	  chain	  3	  beta 478 1.792060494 0.050929733 No Nominal	  p-­‐value 0
row_3 KIAA1109 KIAA1109 KIAA1109 544 1.710649014 0.06962404 No FDR	  q-­‐value 5.04E-­‐04
row_4 ST8SIA1 ST8SIA1 ST8	  alpha-­‐N-­‐acetyl-­‐neuraminide	  alpha-­‐2,8-­‐sialyltransferase	  1 611 1.629442453 0.08721425 No FWER	  p-­‐Value 0.001
row_5 SMIM7 null null 722 1.538029432 0.10128806 No
row_6 SMC4 SMC4 structural	  maintenance	  of	  chromosomes	  4 885 1.410843372 0.11095824 No
row_7 PPIC PPIC peptidylprolyl	  isomerase	  C	  (cyclophilin	  C) 1210 1.200220346 0.10931178 No
row_8 CCR9 CCR9 chemokine	  (C-­‐C	  motif)	  receptor	  9 1284 1.165769219 0.12052943 No
row_9 H3F3B H3F3B H3	  histone,	  family	  3B	  (H3.3B) 1519 1.064026237 0.121892706 No
row_10 EGR2 EGR2 early	  growth	  response	  2	  (Krox-­‐20	  homolog,	  Drosophila) 1588 1.039483428 0.13174096 No
row_11 SDHAF1 null null 1745 0.984709442 0.13621381 No
row_12 USP31 USP31 ubiquitin	  specific	  peptidase	  31 1970 0.915602505 0.1361863 No
row_13 CRIPT CRIPT cysteine-­‐rich	  PDZ-­‐binding	  protein 2043 0.8937971 0.14393681 No
row_14 SESN3 SESN3 sestrin	  3 2562 0.777974069 0.12653776 No
row_15 CSPP1 CSPP1 centrosome	  and	  spindle	  pole	  associated	  protein	  1 2878 0.716659307 0.11910977 No
row_16 SLAMF6 SLAMF6 SLAM	  family	  member	  6 3602 0.604985237 0.088601 No
row_17 ATP1B1 ATP1B1 ATPase,	  Na+/K+	  transporting,	  beta	  1	  polypeptide 4260 0.521278799 0.060508642 No
row_18 IFI27L2 null null 4472 0.495869935 0.055737853 No
row_19 WDR12 WDR12 WD	  repeat	  domain	  12 4548 0.486908525 0.058062874 No
row_20 GID4 null null 5386 0.394062251 0.018778916 No
row_21 GRIA3 GRIA3 glutamate	  receptor,	  ionotrophic,	  AMPA	  3 6236 0.309973687 -­‐0.02222974 No
row_22 SMURF2 SMURF2 SMAD	  specific	  E3	  ubiquitin	  protein	  ligase	  2 6467 0.286243409 -­‐0.030721275 No
row_23 TRIM13 TRIM13 tripartite	  motif-­‐containing	  13 6601 0.272644997 -­‐0.03424511 No
row_24 CYB5D1 CYB5D1 cytochrome	  b5	  domain	  containing	  1 6628 0.271089345 -­‐0.032115098 No
row_25 EIF4E2 EIF4E2 eukaryotic	  translation	  initiation	  factor	  4E	  member	  2 7077 0.228623614 -­‐0.052912492 No
row_26 DIRC2 DIRC2 disrupted	  in	  renal	  carcinoma	  2 7948 0.153479651 -­‐0.097060256 No
row_27 DUSP19 DUSP19 dual	  specificity	  phosphatase	  19 8244 0.129077777 -­‐0.111032814 No
row_28 TMEM50B TMEM50B transmembrane	  protein	  50B 8250 0.128792241 -­‐0.10963099 No
row_29 LYPD6B null null 8499 0.108135678 -­‐0.12138229 No
row_30 TFRC TFRC transferrin	  receptor	  (p90,	  CD71) 8659 0.092881635 -­‐0.12861155 No
row_31 HSPB11 null null 8816 0.077869982 -­‐0.13587601 No
row_32 DPP4 DPP4 dipeptidyl-­‐peptidase	  4	  (CD26,	  adenosine	  deaminase	  complexing	  protein	  2) 9355 0.034692306 -­‐0.163956 No
row_33 HIGD2A HIGD2A HIG1	  domain	  family,	  member	  2A 9507 0.019503452 -­‐0.17171077 No T-­‐Naive	  biased
row_34 UFM1 UFM1 ubiquitin-­‐fold	  modifier	  1 9836 -­‐2.79E-­‐04 -­‐0.18910031 No
row_35 HRSP12 HRSP12 heat-­‐responsive	  protein	  12 9985 -­‐0.014027056 -­‐0.19676688 No
row_36 PSMA5 PSMA5 proteasome	  (prosome,	  macropain)	  subunit,	  alpha	  type,	  5 10051 -­‐0.019558406 -­‐0.19996054 No
row_37 APOOL null null 10453 -­‐0.050357979 -­‐0.22057295 No
row_38 CD69 CD69 CD69	  molecule 10576 -­‐0.061757311 -­‐0.22624302 No
row_39 SF3B14 SF3B14 -­‐ 10679 -­‐0.070999824 -­‐0.2307329 No
row_40 IFT80 IFT80 intraflagellar	  transport	  80	  homolog	  (Chlamydomonas) 10922 -­‐0.094206497 -­‐0.24234633 No
row_41 LTN1 null null 11172 -­‐0.116225645 -­‐0.25404596 No
row_42 CNGA1 CNGA1 cyclic	  nucleotide	  gated	  channel	  alpha	  1 11182 -­‐0.117405698 -­‐0.2530036 No
row_43 TXNL4B TXNL4B thioredoxin-­‐like	  4B 11340 -­‐0.132090256 -­‐0.25961933 No
row_44 PRDX6 PRDX6 peroxiredoxin	  6 11840 -­‐0.177881435 -­‐0.28377792 No
row_45 PHPT1 PHPT1 phosphohistidine	  phosphatase	  1 12049 -­‐0.196422234 -­‐0.2922654 No
row_46 MGST2 MGST2 microsomal	  glutathione	  S-­‐transferase	  2 12218 -­‐0.209586099 -­‐0.29846138 No
row_47 BTF3L4 BTF3L4 basic	  transcription	  factor	  3-­‐like	  4 12266 -­‐0.215067789 -­‐0.29817006 No
row_48 ITGAE ITGAE integrin,	  alpha	  E	  (antigen	  CD103,	  human	  mucosal	  lymphocyte	  antigen	  1;	  alpha	  polypeptide) 12369 -­‐0.225916848 -­‐0.30065483 No
row_49 XKRX XKRX XK,	  Kell	  blood	  group	  complex	  subunit-­‐related,	  X-­‐linked 13020 -­‐0.292157233 -­‐0.33134153 No
row_50 POLR2H POLR2H polymerase	  (RNA)	  II	  (DNA	  directed)	  polypeptide	  H 13272 -­‐0.318979412 -­‐0.34052294 No
row_51 INSIG2 INSIG2 insulin	  induced	  gene	  2 13368 -­‐0.330971003 -­‐0.3412768 No
row_52 RPS2 RPS2 ribosomal	  protein	  S2 13512 -­‐0.347620785 -­‐0.3443605 No
row_53 COPS4 COPS4 COP9	  constitutive	  photomorphogenic	  homolog	  subunit	  4	  (Arabidopsis) 14072 -­‐0.408545583 -­‐0.36871526 No
row_54 CDC26 CDC26 cell	  division	  cycle	  26 14324 -­‐0.437779635 -­‐0.37635902 No
row_55 TTC3 TTC3 tetratricopeptide	  repeat	  domain	  3 14852 -­‐0.500140667 -­‐0.39783135 No
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row_56 CMSS1 null null 14939 -­‐0.513141811 -­‐0.39575008 No
row_57 RPL28 RPL28 ribosomal	  protein	  L28 15661 -­‐0.616440535 -­‐0.42600456 No
row_58 DAPL1 DAPL1 death	  associated	  protein-­‐like	  1 15766 -­‐0.633382142 -­‐0.42332152 No
row_59 PRPS2 PRPS2 phosphoribosyl	  pyrophosphate	  synthetase	  2 15827 -­‐0.644233704 -­‐0.4181648 No
row_60 EEF1E1 EEF1E1 eukaryotic	  translation	  elongation	  factor	  1	  epsilon	  1 15857 -­‐0.648591697 -­‐0.4113078 No
row_61 INPP4B INPP4B inositol	  polyphosphate-­‐4-­‐phosphatase,	  type	  II,	  105kDa 15986 -­‐0.673618138 -­‐0.40937668 No
row_62 UBE2H UBE2H ubiquitin-­‐conjugating	  enzyme	  E2H	  (UBC8	  homolog,	  yeast) 16554 -­‐0.794251204 -­‐0.4291634 Yes
row_63 RAB3IP RAB3IP RAB3A	  interacting	  protein	  (rabin3) 16744 -­‐0.841588676 -­‐0.4282929 Yes
row_64 RPS14 RPS14 ribosomal	  protein	  S14 16751 -­‐0.84301734 -­‐0.4176998 Yes
row_65 RAPGEF4 RAPGEF4 Rap	  guanine	  nucleotide	  exchange	  factor	  (GEF)	  4 16777 -­‐0.849250078 -­‐0.40803358 Yes
row_66 TRIB2 TRIB2 tribbles	  homolog	  2	  (Drosophila) 16878 -­‐0.874607146 -­‐0.40201622 Yes
row_67 TCP11L2 TCP11L2 t-­‐complex	  11	  (mouse)	  like	  2 17003 -­‐0.911212921 -­‐0.39679775 Yes
row_68 CCNT1 CCNT1 cyclin	  T1 17122 -­‐0.946210921 -­‐0.39080814 Yes
row_69 KLHDC2 KLHDC2 kelch	  domain	  containing	  2 17130 -­‐0.947930574 -­‐0.37891015 Yes
row_70 EIF3H null null 17334 -­‐1.021437287 -­‐0.37645426 Yes
row_71 RPL15 RPL15 ribosomal	  protein	  L15 17431 -­‐1.054984808 -­‐0.36789015 Yes
row_72 UXT UXT ubiquitously-­‐expressed	  transcript 17544 -­‐1.100017428 -­‐0.35959163 Yes
row_73 EMG1 EMG1 EMG1	  nucleolar	  protein	  homolog	  (S.	  cerevisiae) 17854 -­‐1.251248837 -­‐0.3597822 Yes
row_74 COX4I1 COX4I1 cytochrome	  c	  oxidase	  subunit	  IV	  isoform	  1 17856 -­‐1.251396775 -­‐0.34363824 Yes
row_75 RANGRF null null 17993 -­‐1.332128406 -­‐0.33360818 Yes
row_76 CYB5A CYB5A cytochrome	  b5	  type	  A	  (microsomal) 18277 -­‐1.537228465 -­‐0.32871854 Yes
row_77 SELL SELL selectin	  L	  (lymphocyte	  adhesion	  molecule	  1) 18346 -­‐1.622110724 -­‐0.31132928 Yes
row_78 SATB1 SATB1 special	  AT-­‐rich	  sequence	  binding	  protein	  1	  (binds	  to	  nuclear	  matrix/scaffold-­‐associating	  DNA's) 18441 -­‐1.738813519 -­‐0.29380825 Yes
row_79 CCR7 CCR7 chemokine	  (C-­‐C	  motif)	  receptor	  7 18540 -­‐1.883787751 -­‐0.27462292 Yes
row_80 DPH5 DPH5 DPH5	  homolog	  (S.	  cerevisiae) 18602 -­‐1.983968496 -­‐0.2521789 Yes
row_81 ST13 ST13 suppression	  of	  tumorigenicity	  13	  (colon	  carcinoma)	  (Hsp70	  interacting	  protein) 18665 -­‐2.091876268 -­‐0.22839125 Yes
row_82 IFNGR2 IFNGR2 interferon	  gamma	  receptor	  2	  (interferon	  gamma	  transducer	  1) 18693 -­‐2.151143551 -­‐0.20198052 Yes
row_83 ITGA6 ITGA6 integrin,	  alpha	  6 18759 -­‐2.333361864 -­‐0.17522638 Yes
row_84 PDK1 PDK1 pyruvate	  dehydrogenase	  kinase,	  isozyme	  1 18859 -­‐2.859877586 -­‐0.14346042 Yes
row_85 LSM7 LSM7 LSM7	  homolog,	  U6	  small	  nuclear	  RNA	  associated	  (S.	  cerevisiae) 18862 -­‐2.890331745 -­‐0.1061566 Yes
row_86 LEF1 LEF1 lymphoid	  enhancer-­‐binding	  factor	  1 18933 -­‐4.036038399 -­‐0.057629675 Yes
row_87 ACTN1 ACTN1 actinin,	  alpha	  1 18942 -­‐4.497610569 1.59E-­‐04 Yes
